NA-Semax (N-Acetyl Semax Amidate) is a modified form of Semax, a synthetic heptapeptide analogue of ACTH(4-10) — the biologically active fragment of adrenocorticotropic hormone. Semax itself was developed at the Institute of Molecular Genetics in Moscow and has been registered as a pharmaceutical in Russia since 1994 for neurological and cognitive applications.[1]

The NA-Semax modification adds an N-terminal acetyl group and a C-terminal amide to the native Semax sequence (Met-Glu-His-Phe-Pro-Gly-Pro). These modifications are designed to increase enzymatic stability and potentially enhance blood-brain barrier penetration, extending the functional duration beyond that of unmodified Semax.[2]

Compound Profile

What Does NA-Semax Actually Do?

NA-Semax’s biological activity is inferred primarily from the Semax research literature, as dedicated studies on the N-acetyl amide modification are extremely limited. Semax research demonstrates neuroprotective, nootropic, and immunomodulatory properties through ACTH-related signalling pathways.[1][2]

The parent compound Semax has shown neuroprotective effects in multiple experimental models. Recent research demonstrated Semax’s ability to compensate for gene expression disruption in rat brain following experimental ischaemic stroke, modulating transcriptomic profiles toward recovery patterns within 24 hours of insult.[3] Whether the NA modification enhances these effects, merely extends their duration, or alters the pharmacological profile is not established by direct comparative research.

How NA-Semax Works

The mechanism of action is understood through Semax research, which has identified several molecular pathways:[1][2]

BDNF and neurotrophic signalling: Semax has been shown to upregulate brain-derived neurotrophic factor (BDNF) and other neurotrophic factors. This BDNF-enhancing effect is one of the most consistently reported findings across Semax studies and is considered a key mechanism underlying its neuroprotective and cognitive-enhancing properties.

Gene expression modulation: Large-scale transcriptomic studies have demonstrated that Semax and ACTH-like peptides modulate immune gene expression patterns in brain regions following ischaemia. These peptides appear to compensate for stroke-induced transcriptomic disruption, restoring expression patterns toward baseline.[3][4]

Calcium signalling: Recent research has demonstrated that Semax affects intracellular calcium dynamics in rat brain neurons, suggesting effects on neuronal excitability and signalling at the cellular level.[5]

Opioid receptor interaction: Novel research has identified that Semax targets the mu opioid receptor gene Oprm1, promoting deubiquitination and functional recovery in spinal cord injury models. This previously unrecognised mechanism suggests broader pharmacological activity than initially understood.[6]

Antidepressant and anti-stress effects: Comparative studies have demonstrated antidepressant-like and anti-stress effects of Semax in forced swim and chronic stress paradigms, with efficacy comparable to other ACTH-derived peptides.[7]

The N-acetylation and C-amidation modifications in NA-Semax are standard peptide chemistry approaches to enhance metabolic stability. The acetyl group protects against aminopeptidase degradation at the N-terminus, while the amide protects against carboxypeptidase degradation at the C-terminus.

Longevity / Healthy Aging Context

Semax-derived peptides are investigated within longevity and healthy aging research primarily through the lens of neuroprotection and cognitive preservation. Age-related neurodegenerative decline involves many of the same pathways that Semax modulates — BDNF reduction, neuroinflammation, oxidative stress, and impaired calcium homeostasis.[1]

The neuroprotective effects demonstrated in ischaemic stroke models — gene expression compensation, immune modulation, calcium signalling regulation — are relevant to age-related neurological decline, though the connection is inferential rather than directly demonstrated in aging populations.[3][4]

No clinical longevity studies have been conducted with NA-Semax specifically. The longevity context is extrapolated from acute neuroprotection data in injury models. Compare with Semax, Selank, and Cortexin for related neuroprotective profiles, or see the Longevity / Healthy Aging goal page.

Recovery & Sleep Context

Semax’s demonstrated effects on neurological recovery from ischaemia position it within the recovery research context. The ability to modulate post-ischaemic gene expression toward recovery patterns and reduce inflammatory cascades in brain tissue suggests relevance to neurological recovery processes.[3][4]

The anti-stress and antidepressant-like effects observed in animal models could theoretically influence recovery through stress-axis modulation. Chronic stress impairs recovery processes, and ACTH-derived peptides that modulate HPA axis signalling may indirectly support recovery by reducing stress-mediated interference.[7]

Direct evidence linking NA-Semax to recovery outcomes or sleep quality does not exist. The recovery context for NA-Semax specifically is entirely inferred from parent compound Semax data. See the Recovery & Sleep goal page for broader context.

NA-Semax Benefits

• Enhanced stability: The N-acetyl and C-amide modifications are designed to improve enzymatic resistance compared to unmodified Semax, potentially extending functional duration.
• BDNF upregulation (from Semax data): The parent compound consistently demonstrates BDNF enhancement in preclinical models — one of the most reproducible findings in the Semax literature.[1]
• Neuroprotective gene modulation: Semax compensates for ischaemia-induced transcriptomic disruption, a mechanism with broad relevance to neuroprotection.[3][4]
• Novel opioid receptor mechanism: Recent discovery of mu opioid receptor gene targeting adds a previously unrecognised mechanistic dimension to Semax pharmacology.[6]
• Multi-pathway activity: Unlike single-target compounds, Semax-derived peptides modulate neurotrophic, immune, and calcium signalling pathways simultaneously.[1][5]

NA-Semax Side Effects

No dedicated safety studies for NA-Semax have been conducted. Side effect considerations are inferred from Semax research and general peptide pharmacology:

• ACTH-related effects: As an ACTH(4-10) analogue, theoretical concerns about HPA axis modulation exist, though Semax at studied concentrations did not produce significant cortisol or ACTH-like endocrine effects.
• Nasal irritation: If administered intranasally (the most common Semax delivery route), local mucosal irritation is a theoretical concern.
• Unknown modification effects: The acetylation and amidation modifications could theoretically alter the side effect profile compared to native Semax. No data exists to confirm or rule this out.
• Semax safety record: The parent compound Semax has been used pharmaceutically in Russia since 1994 with reports of generally good tolerability. Whether this safety record transfers to the modified NA form is unconfirmed.

Half-Life

Native Semax has a relatively short half-life, estimated at minutes when administered without modification. The N-acetylation and C-amidation in NA-Semax are specifically designed to extend this duration by protecting against exopeptidase degradation at both termini.

Exact pharmacokinetic data for NA-Semax has not been published. The expected half-life extension from these modifications is modest — likely extending functional activity to the range of hours rather than minutes — based on analogous peptide modification data in the literature.

Limits of Current Evidence

• No dedicated NA-Semax studies: Essentially all evidence is borrowed from the parent Semax literature. NA-Semax has not been independently characterised in published research.
• Modification effects unknown: Whether N-acetylation and C-amidation alter efficacy, selectivity, or side effect profile compared to native Semax is entirely uncharacterised.
• No pharmacokinetic data: The presumed half-life extension has not been measured or published.
• Semax evidence limitations: Even the parent compound’s clinical evidence is predominantly from Russian sources, with limited international replication.
• Nootropic claims exceed data: NA-Semax is marketed in nootropic communities with claims that substantially exceed the available evidence, particularly regarding cognitive enhancement in healthy individuals.

Verdict

NA-Semax is essentially Semax with protective chemical modifications — acetylation and amidation — designed to improve metabolic stability. The parent compound Semax has a legitimate pharmacological pedigree as a Russian-registered pharmaceutical with decades of clinical use and a growing body of mechanistic research including novel findings on opioid receptor targeting and transcriptomic modulation.

However, NA-Semax itself has no independent research characterisation. Every claimed benefit is borrowed from Semax studies. While the chemical modifications are pharmacologically rational and well-established in peptide chemistry, assuming they produce an unambiguously superior compound without data is speculative. For researchers interested in ACTH-derived neuropeptides, the Semax literature provides the evidence base — NA-Semax adds stability engineering but zero additional efficacy data.

FAQ

What is NA-Semax amidate?

NA-Semax amidate (N-Acetyl Semax Amidate) is a chemically modified version of the peptide Semax, a synthetic analogue of ACTH(4-10). The N-acetyl group and C-terminal amide are added to improve enzymatic stability and potentially extend the peptide’s functional duration compared to unmodified Semax.

What is the difference between Semax and NA-Semax?

The difference is chemical modification: NA-Semax adds an acetyl group to the N-terminus and an amide to the C-terminus of the native Semax sequence. These protect against enzymatic degradation, theoretically extending half-life. However, no published studies directly compare their pharmacological profiles, and all efficacy claims for NA-Semax are inferred from Semax research.

Is NA-Semax a nootropic?

NA-Semax is marketed as a nootropic based on the parent compound Semax’s neuroprotective and cognitive research profile, which includes BDNF upregulation and neuroprotective gene modulation. However, no dedicated cognitive enhancement studies have been conducted with NA-Semax specifically, and Semax’s own clinical nootropic evidence is primarily from Russian sources.

What are NA-Semax side effects?

No dedicated safety data exists for NA-Semax. Side effect expectations are based on the parent compound Semax, which has been used pharmaceutically in Russia since 1994 with reports of generally good tolerability. Common theoretical concerns include nasal irritation (if administered intranasally) and potential HPA axis effects.

How does NA-Semax compare to Selank?

Both are synthetic peptides developed in Russia for neurological applications. Semax (and by extension NA-Semax) derives from ACTH(4-10) and is primarily studied for neuroprotection and cognitive enhancement. Selank derives from tuftsin and is primarily studied for anxiolytic and anti-anxiety effects. They target overlapping but distinct neurological domains.

Is NA-Semax approved for medical use?

No. NA-Semax is not approved for medical use in any country. The parent compound Semax is registered as a pharmaceutical in Russia for neurological indications, but this regulatory status does not extend to the NA-modified analogue.

References

1. Radchenko AI. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model. Acta Naturae. 2025. PMID: 41479572
2. Giri S, et al. Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases. Neuropeptides. 2025. PMID: 41004910
3. Filippenkov IB, et al. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. 2024. PMID: 39767736
4. Filippenkov IB, et al. Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain. Genes. 2023. PMID: 37510287
5. Kolbaev SN. The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons. Bull Exp Biol Med. 2025. PMID: 41171324
6. Liu R, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury. Br J Pharmacol. 2025. PMID: 40692165
7. Inozemtseva LS, et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II. Eur J Pharmacol. 2024. PMID: 39442746

Cortexin is a complex neuropeptide preparation derived from the cerebral cortex of cattle and pigs. Unlike single-sequence peptides, cortexin contains a mixture of low-molecular-weight polypeptides (molecular weight up to 10 kDa), amino acids, vitamins, and trace minerals extracted through a standardised purification process. It has been registered as a pharmaceutical preparation in Russia and several CIS countries since 1999, primarily for neurological indications.[1][2]

Research interest in cortexin centres on its multi-target neuroprotective profile — rather than acting through a single receptor, the peptide mixture appears to modulate multiple pathways simultaneously, including apoptosis inhibition, antioxidant defence, and neurotrophic factor expression. This polypharmacological approach distinguishes cortexin from single-peptide neuroprotective agents.[1]

Compound Profile

What Does Cortexin Actually Do?

Cortexin research demonstrates a multi-modal neuroprotective profile. In preclinical models of cerebral ischaemia, cortexin reduced infarct volume, improved neurological deficit scores, and preserved memory function. Comparative studies with cerebrolysin and actovegin showed cortexin produced comparable or superior protective effects on memory and cerebral circulation markers.[3]

The peptide preparation has been investigated across a range of neurological conditions in clinical settings, including ischaemic stroke, traumatic brain injury, cognitive impairment, and paediatric neurodevelopmental conditions. Russian-language clinical literature reports consistent improvement in cognitive scores and neurological function, though these studies vary in methodological rigour by Western trial standards.[4]

How Cortexin Works

Cortexin’s mechanism of action involves multiple convergent neuroprotective pathways, consistent with its multi-peptide composition. Research has identified several key molecular targets:[1][2]

Anti-apoptotic activity: Cortexin inhibits brain caspase-8, a key initiator of the extrinsic apoptosis pathway. This anti-apoptotic effect is particularly relevant in ischaemic brain injury, where delayed neuronal death through caspase cascades significantly expands initial lesion size.[5]

Antioxidant defence: Comparative studies demonstrated cortexin’s antioxidant effects in chronic cerebrovascular insufficiency models, with efficacy comparable to cerebrolysin in reducing oxidative stress markers. The antioxidant mechanism appears to involve both direct radical scavenging and upregulation of endogenous antioxidant enzymes.[4]

Neurotrophic factor modulation: Cortexin has been shown to influence BDNF (brain-derived neurotrophic factor) levels and modulate epigenetic mechanisms including expression of the neuroprotective protein FKBP1b — a regulator of calcium signalling implicated in age-related cognitive decline.[6]

Ion channel modulation: Recent research demonstrated cortexin modulates OPG/RANK/RANKL signalling and TRPC1 (transient receptor potential canonical 1) expression in cerebral ischaemia-reperfusion injury, suggesting effects on calcium homeostasis and neuroinflammatory cascades.[7]

Longevity / Healthy Aging Context

Cortexin’s neuroprotective profile positions it within longevity and healthy aging research, particularly regarding cognitive preservation during aging. The peptide’s effects on BDNF levels, caspase inhibition, and antioxidant defence are all relevant to age-related neurodegeneration mechanisms.[1][6]

Russian gerontological research has investigated cortexin alongside other bioregulatory peptides (including Epithalon and thymalin) within a broader framework of peptide bioregulation theory. This research tradition, led by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides derived from organ-specific extracts can restore age-related functional decline in their tissue of origin.[6]

However, rigorous longitudinal studies demonstrating cortexin’s effects on cognitive aging trajectories in healthy populations are lacking. The longevity context is extrapolated from acute neuroprotection data rather than demonstrated in aging-specific endpoints. See the Longevity / Healthy Aging goal page for broader context. Compare with Humanin and Epithalon for related neuroprotective and longevity-focused profiles.

Recovery & Sleep Context

Cortexin’s most clinically documented application falls within the recovery context — specifically, neurological recovery following ischaemic stroke and traumatic brain injury. Russian clinical studies report improved neurological deficit scores and cognitive recovery timelines when cortexin is added to standard rehabilitation protocols.[3][4]

A prospective, double-blinded comparative study assessed cortexin alongside cerebrolysin and other neuropeptide preparations in neurological recovery contexts, providing some of the more methodologically rigorous evidence available for the compound.[8]

Direct evidence for cortexin effects on sleep architecture is limited. The recovery context is derived primarily from neurological rehabilitation data rather than sleep-specific endpoints. See the Recovery & Sleep goal page for broader context.

Cortexin Benefits

• Multi-target neuroprotection: Research demonstrates simultaneous action on apoptosis, oxidative stress, neurotrophic signalling, and calcium homeostasis — a polypharmacological profile uncommon in single-peptide agents.[1][2][7]
• Clinical track record: Registered pharmaceutical in Russia/CIS since 1999 with extensive clinical use in neurology departments, providing real-world safety and efficacy observations beyond preclinical data alone.
• Caspase-8 inhibition: Direct inhibition of the extrinsic apoptosis initiator represents a specific, validated molecular mechanism for cortexin’s neuroprotective effects.[5]
• Comparative efficacy data: Head-to-head preclinical comparisons with cerebrolysin and actovegin provide context for cortexin’s relative efficacy within the brain peptide extract class.[3][4]
• Neuropathy protection: Preclinical data demonstrates cortexin ameliorates high glucose-induced neuropathy in sensory neurons, suggesting applications beyond ischaemic injury.[9]

Cortexin Side Effects

Cortexin has accumulated a substantial clinical safety record through its pharmaceutical use in Russia and CIS countries. Reported adverse effects include:

• Injection site reactions: Local pain, redness, or swelling at intramuscular injection sites — the most commonly reported adverse effect.
• Allergic reactions: Rare hypersensitivity reactions have been reported, consistent with the animal-derived protein composition of the preparation.
• Prion risk (theoretical): As a bovine/porcine brain-derived product, theoretical concerns about transmissible spongiform encephalopathy exist, though no cases have been reported and manufacturing processes include purification steps designed to reduce this risk.
• Generally well-tolerated: Clinical studies consistently report low discontinuation rates due to adverse events, with the safety profile described as favourable relative to other neuroactive medications.

Half-Life

As a complex multi-peptide mixture, cortexin does not have a single defined pharmacokinetic half-life. The constituent polypeptides have varying molecular weights (up to 10 kDa) and would be expected to have different clearance rates. Clinical dosing protocols typically use once-daily intramuscular injection over courses of 10–20 days, suggesting the biological effects are cumulative rather than dependent on sustained plasma levels of any single component.

Limits of Current Evidence

• Limited Western clinical trials: The vast majority of clinical evidence is published in Russian-language journals, with few studies meeting Western regulatory trial design standards (randomisation, blinding, adequate power).
• Complex composition: As a multi-component extract, identifying which specific peptides drive biological activity is challenging. Batch-to-batch compositional variability is a concern.
• Regulatory status: Not approved by the FDA, EMA, or other major Western regulatory bodies. Registered only in Russia and select CIS/Asian countries.
• Publication bias: Clinical literature is predominantly from research groups with commercial or institutional relationships to cortexin production, raising standard conflict-of-interest considerations.
• Comparator limitations: Most comparative studies test cortexin against other neuropeptide preparations (cerebrolysin, actovegin) rather than against placebo in adequately powered designs.

Verdict

Cortexin occupies an interesting position in the neuropeptide landscape — a multi-component brain extract with genuine molecular mechanisms (caspase-8 inhibition, BDNF modulation, TRPC1 regulation) and decades of clinical use in Russian neurology, yet limited acceptance in Western medicine due to insufficient trial evidence meeting international standards.

The preclinical data is scientifically credible, with mechanisms validated in reproducible models. However, the translational confidence requires acknowledging that clinical evidence is largely confined to Russian-language literature with variable methodological quality. For researchers interested in polypharmacological neuroprotection, cortexin provides a documented example of the multi-peptide approach — but evidence confidence should reflect the geographical and methodological limitations of the clinical data.

FAQ

What is cortexin peptide?

Cortexin is a complex neuropeptide preparation derived from the cerebral cortex of cattle and pigs. It contains a mixture of low-molecular-weight polypeptides (up to 10 kDa), amino acids, vitamins, and trace minerals. It has been registered as a pharmaceutical in Russia since 1999 for neurological conditions.

Is cortexin a nootropic?

Cortexin is classified as a neuroprotective and nootropic agent in Russian pharmacology. Research suggests it modulates multiple neuroprotective pathways including anti-apoptotic activity, antioxidant defence, and neurotrophic factor expression. However, its classification as a nootropic is based primarily on Russian clinical literature rather than international regulatory evaluation.

What are cortexin side effects?

The most commonly reported side effects of cortexin are injection site reactions (pain, redness) from intramuscular administration. Rare allergic reactions have been documented. Clinical studies in Russia report generally favourable tolerability with low discontinuation rates due to adverse events.

How does cortexin compare to cerebrolysin?

Both are animal-derived brain peptide preparations. Cerebrolysin is derived from porcine brain and has more extensive Western clinical trial data, including large stroke trials. Cortexin is derived from bovine/porcine cerebral cortex and has broader Russian clinical use. Preclinical comparative studies show similar efficacy profiles with some differences in specific neuroprotective endpoints.

Is cortexin approved by the FDA?

No. Cortexin is not approved by the FDA, EMA, or other major Western regulatory agencies. It is registered as a pharmaceutical preparation in Russia and several CIS countries, where it has been used clinically since 1999.

What is cortexin mechanism of action?

Cortexin acts through multiple converging mechanisms: inhibition of brain caspase-8 (anti-apoptotic), antioxidant defence enhancement, BDNF modulation, TRPC1/calcium channel regulation, and epigenetic modulation of neuroprotective proteins like FKBP1b. This multi-target profile reflects its complex multi-peptide composition.

References

1. Gulyaeva NV. Molecular mechanisms of brain peptide-containing drugs: cortexin. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018. PMID: 30499504
2. Kuznik BI. Epigenetic Mechanisms of Peptide-Driven Regulation and Neuroprotective Protein FKBP1b. Molekuliarnaia Biologiia. 2019. PMID: 31099784
3. Tyurenkov IN, et al. Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and brain morphology. Zhurnal Nevrologii i Psikhiatrii. 2020. PMID: 32929929
4. Kurkin DV, et al. Antioxidant effect of cortexin, cerebrolysin and actovegin in rats with chronic cerebrovascular insufficiency. Zhurnal Nevrologii i Psikhiatrii. 2021. PMID: 34460162
5. Yakovlev AA. Peptide drug cortexin inhibits brain caspase-8. Biomeditsinskaia Khimiia. 2017. PMID: 28251948
6. Kuznik BI. Epigenetic Mechanisms of Peptide-Driven Regulation and Neuroprotective Protein FKBP1b. Molekuliarnaia Biologiia. 2019. PMID: 31099784
7. Guven C. Cortexin modulates OPG/RANK/RANKL and TRPC1 expression in cerebral ischemia-reperfusion injury. Neurological Research. 2026. PMID: 40783844
8. Zhang L, et al. Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations. J Neurol Sci. 2019. PMID: 30665068
9. Yazar U. Cortexin ameliorates high glucose-induced neuropathy in cultured rat sensory neurons. Neuroendocrinology. 2023. PMID: 37080184

Pinealon is a synthetic tripeptide composed of the amino acid sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, or EDR). It belongs to a family of ultrashort peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson. The pinealon peptide was designed as a synthetic analogue of naturally occurring regulatory sequences isolated from pineal gland extract (Epithalamin).

As a tripeptide, pinealon has a molecular weight of just 419.39 g/mol and a correspondingly brief half-life measured in minutes. Despite its small size, preclinical research suggests that this short peptide bioregulator may interact directly with DNA sequences and influence gene expression — a mechanism that distinguishes it from classical receptor-mediated peptide signalling. The compound is primarily investigated for its potential neuroprotective properties, particularly in the context of age-related cognitive decline and neurodegenerative disease models.

It is important to note that pinealon is not a drug candidate in any Western pharmaceutical pipeline. It exists entirely within the Khavinson peptide bioregulation research paradigm, a framework that has attracted both interest and scepticism from the broader scientific community.

Compound Profile

Origins & Bioregulator Theory

The Khavinson bioregulator programme began in the 1970s–1980s at the Military Medical Academy in St. Petersburg. The original hypothesis proposed that short peptide sequences, derived from organ-specific tissue extracts, could restore normal gene expression patterns in ageing or damaged tissues. This concept led to the development of a family of compounds including Epithalon (from pineal extract, targeting telomerase), Thymalin (from thymus extract), and Cortexin (from brain cortex extract).

Pinealon emerged as part of the second generation of these bioregulators — synthetic tripeptides intended to replicate the activity of the longer, naturally derived peptide mixtures. Where Epithalamin was a complex pineal gland extract, pinealon represents a minimised synthetic sequence (EDR) proposed to capture the neuroactive component of that extract. This approach reflects the broader short peptide bioregulator philosophy: that very small peptide sequences can serve as epigenetic signals, modulating gene expression without acting through conventional cell surface receptors.

The theoretical framework underpinning these compounds remains contested. While Khavinson’s group has published extensively — including a systematic review of peptide regulation of gene expression — independent replication of these findings by laboratories outside the Russian/CIS research network remains limited. This is a critical caveat when evaluating the evidence for pinealon and related Khavinson peptides.

Mechanism of Action

The proposed mechanism of action for the pinealon peptide differs fundamentally from that of most conventional peptide therapeutics. Rather than binding cell surface receptors, preclinical data suggests that short peptides like EDR can penetrate cell membranes and enter the nucleus, where they interact directly with specific DNA sequences.

Fedoreyeva et al. (2011) demonstrated in HeLa cell cultures that fluorescently labelled short peptides — including EDR — could penetrate into the cell nucleus and interact with specific deoxyribooligonucleotide sequences in vitro. This finding supports the hypothesis that these ultrashort peptides act at an epigenetic level, potentially influencing chromatin remodelling and gene transcription rather than triggering conventional signal transduction cascades.

Silanteva et al. (2019) further characterised the physical chemistry of EDR–DNA interactions, demonstrating that the binding is influenced by ionic conditions and that the peptide forms stable complexes with DNA in the presence of divalent cations. This work provides a biophysical basis for understanding how such a small molecule could interact with genetic material, though the functional consequences of these interactions in living systems remain less well established.

A 2020 review by Khavinson et al. specifically explored the possible mechanisms by which the EDR peptide might regulate gene expression and protein synthesis relevant to Alzheimer’s disease pathogenesis, proposing effects on genes involved in neuronal survival and amyloid processing. However, much of this mechanistic framework remains theoretical and requires independent validation.

Neuroprotective Evidence

The primary research interest in pinealon centres on its potential neuroprotective properties. The available preclinical evidence, while limited in scope, suggests several potentially relevant biological activities.

In a 2011 study published in Rejuvenation Research, Khavinson et al. reported that pinealon increased cell viability in neuronal cultures by suppressing free radical levels and activating proliferative processes. The study demonstrated reduced markers of oxidative stress in cells treated with the peptide, suggesting a protective effect against one of the primary mechanisms of age-related neuronal damage.

Kraskovskaya et al. (2017) investigated the effects of tripeptides including EDR on neuronal spine density in an in vitro model of Alzheimer’s disease. The study reported that treatment with these short peptide bioregulators restored neuronal spine numbers under conditions that modelled amyloid-beta toxicity. Dendritic spine loss is a well-established correlate of cognitive decline in Alzheimer’s disease, making this finding potentially significant — though the in vitro nature of the experiment limits direct clinical extrapolation.

A 2021 study by Khavinson et al. extended these findings to an animal model, examining the neuroprotective effects of tripeptide epigenetic regulators — including EDR — in a mouse model of Alzheimer’s disease. The researchers reported improvements in markers associated with neurodegeneration, though the study was conducted by the same research group that developed the compound.

Cognitive & Brain Ageing Research

Several studies have examined pinealon’s effects on cognitive function in aged animals, positioning the pinealon nootropic hypothesis within the broader context of brain ageing research.

Mendzheritsky et al. (2015) investigated pinealon brain effects alongside Cortexin in 18-month-old rats subjected to hypoxia and hypothermia. The study reported that pinealon influenced behavioural outcomes and neurochemical processes, including alterations in caspase-3 activity — an enzyme central to apoptotic pathways. These findings suggest that the peptide may modulate neuronal survival under stress conditions, though the study was conducted in Russian and published in a specialist gerontology journal.

Earlier work by the same group (Mendzheritsky et al., 2013) examined the effects of peptide geroprotectors on navigation-system learning and caspase-3 activity across different brain structures in rats of varying ages. The results indicated age-dependent effects, with older animals showing more pronounced responses to peptide treatment — a finding consistent with the bioregulator theory’s prediction that these peptides primarily restore function in aged or damaged tissues rather than enhancing already-optimal function.

The research on pinealon benefits for cognitive function, while suggestive, must be interpreted with caution. All animal cognitive studies to date have been conducted within the Russian/CIS research network, and the specific experimental paradigms used may not directly translate to cognitive outcomes measured in Western research frameworks.

Pineal Function & Sleep Research

Given its derivation from pineal gland extract, questions about pinealon sleep effects and pineal gland function are understandable. The pineal gland’s primary endocrine function is the production of melatonin, the hormone that regulates circadian rhythm and sleep-wake cycles.

Khavinson et al. (2011) examined the effect of short peptides on signalling molecule expression in organotypic pineal cell cultures. The study reported that EDR influenced the expression of certain signalling molecules within pineal tissue, suggesting a possible modulatory role in pineal gland function. However, the step from in vitro pineal cell effects to meaningful pinealon sleep benefits in living organisms requires considerably more evidence than currently exists.

The relationship between pinealon and melatonin synthesis is indirect at best. While the peptide was derived from pineal gland extracts, its primary research focus has been neuroprotection rather than circadian regulation. Any effects on sleep would likely be secondary to broader neuromodulatory actions rather than direct melatonin pathway stimulation. Researchers interested in peptides with more direct sleep-related mechanisms may wish to explore DSIP (delta-sleep-inducing peptide), which has a more established research base in this domain.

Safety & Side Effects

Data on pinealon side effects is extremely limited, reflecting the early stage and narrow scope of the existing research. The available preclinical literature does not report significant toxicity or adverse effects at the concentrations studied, but this should not be interpreted as evidence of safety in humans.

Several factors are worth considering when evaluating the safety profile:

• Tripeptide structure: As a tripeptide composed of three common amino acids (glutamic acid, aspartic acid, arginine), pinealon is rapidly metabolised and has a half-life measured in minutes. This rapid clearance may limit both therapeutic effects and toxic potential.
• Limited human data: While some Russian-language publications describe clinical observations with peptide bioregulator combinations, controlled safety studies meeting international regulatory standards have not been published for pinealon specifically.
• No regulatory evaluation: Pinealon has not undergone formal toxicological evaluation by any major regulatory body (EMA, MHRA, FDA). Standard safety pharmacology studies that would typically precede clinical development have not been published in accessible literature.
• Unknown long-term effects: The proposed epigenetic mechanism of action — modulating gene expression — raises theoretical questions about long-term effects that have not been addressed in the current literature.

The absence of reported pinealon side effects in preclinical studies should be understood as reflecting limited investigation rather than confirmed safety. This is a common pattern with early-stage research compounds that have not progressed to systematic safety evaluation.

Research Limitations

Transparency about the significant limitations of the pinealon evidence base is essential for any honest evaluation of this compound. Several critical issues warrant emphasis:

Single research group: The overwhelming majority of published pinealon research originates from the St. Petersburg Institute of Bioregulation and Gerontology and affiliated laboratories. While this is not unusual for a compound in early development, the absence of meaningful independent replication by unaffiliated research groups is a substantial limitation. Science relies on reproducibility, and the pinealon literature has not yet demonstrated this.

Mostly preclinical: The evidence base consists primarily of cell culture experiments and animal studies. No controlled clinical trials meeting international standards have been published. The small number of clinical observations that exist were conducted within the same research network and published predominantly in Russian-language journals.

Unconventional mechanism: The proposed mechanism — direct peptide-DNA interaction leading to epigenetic modulation — is genuinely novel but also unorthodox. While biophysical studies have demonstrated that EDR can bind DNA in vitro, the functional significance of these interactions in complex biological systems remains to be conclusively established.

Publication ecosystem: Much of the supporting literature appears in journals with limited international peer review penetration, including Advances in Gerontology (Uspekhi Gerontologii) and the Bulletin of Experimental Biology and Medicine. While these are legitimate scientific publications, they operate within a different peer review culture than high-impact international journals.

Theoretical framework: The broader Khavinson bioregulator paradigm — while internally consistent — has not been widely adopted by the international research community. This does not necessarily invalidate the science, but it does mean that the theoretical framework itself requires independent evaluation alongside the specific experimental claims.

Verdict

Pinealon is a scientifically interesting compound with a genuinely novel proposed mechanism, but the current evidence base is insufficient to draw firm conclusions about its efficacy or practical utility. The preclinical data on neuroprotection and cognitive effects in aged animals is suggestive but comes almost entirely from a single research network.

The compound scores 6.5/10 for neuroprotection and cognition research interest and 6.0/10 for longevity and anti-ageing relevance — reflecting the theoretical potential of the bioregulator approach alongside the significant evidence gaps that currently exist. For researchers interested in the broader Khavinson peptide bioregulation paradigm, pinealon represents one piece of a larger theoretical puzzle that encompasses Epithalon and related short peptides.

Until independent replication of the core findings is published, pinealon should be regarded as an early-stage research compound with preclinical promise but unresolved questions about its biological activity, safety, and relevance to human health. Researchers seeking neuroprotective peptides with stronger evidence bases may find Semax, Selank, or Cerebrolysin to be better-supported starting points.

FAQ

What is pinealon?

Pinealon is a synthetic tripeptide with the amino acid sequence Glu-Asp-Arg (EDR). It was developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of Professor Vladimir Khavinson’s short peptide bioregulator programme. The compound is derived from pineal gland extract and is primarily researched for potential neuroprotective properties.

How does pinealon differ from epithalon?

Both pinealon and epithalon are synthetic tripeptides from the Khavinson bioregulator programme, but they have different sequences and proposed targets. Epithalon (AEDG) is primarily researched for telomerase activation and anti-ageing effects, while pinealon (EDR) focuses on neuroprotection and gene expression regulation related to neuronal survival. They share the same research origins but represent different branches of the bioregulator concept.

What does the research say about pinealon and neuroprotection?

Preclinical studies suggest that pinealon may protect neurons against oxidative stress, restore dendritic spine density in Alzheimer’s disease models, and influence caspase-3 activity (an apoptosis-related enzyme) in aged animal brains. However, these findings come predominantly from a single research group and have not been independently replicated by international laboratories.

Does pinealon affect sleep?

While pinealon is derived from pineal gland extract — the gland responsible for melatonin production — there is no robust evidence directly linking pinealon to sleep improvements. In vitro studies show it can influence signalling molecules in pineal cell cultures, but the step from this to meaningful sleep effects has not been demonstrated. Researchers interested in sleep-related peptides may wish to explore DSIP instead.

What are the known side effects of pinealon?

There is very limited data on pinealon side effects. Preclinical studies have not reported significant toxicity, but no formal safety pharmacology studies meeting international regulatory standards have been published. The absence of reported adverse effects reflects limited investigation rather than confirmed safety.

Is pinealon a nootropic?

Pinealon is sometimes described as a nootropic due to animal studies showing improved cognitive performance in aged rats. However, this classification is premature given the limited and predominantly preclinical nature of the evidence. The proposed mechanism — epigenetic modulation of gene expression — differs from conventional nootropic pathways, and no human cognitive trials have been published.

How does pinealon compare to semax and selank?

Both semax and selank are Russian-developed neuropeptides with substantially larger evidence bases than pinealon. Both have achieved registered pharmaceutical status in Russia and have more conventional, better-characterised mechanisms of action. Pinealon remains at an earlier research stage with a more speculative mechanism.

What is the evidence confidence level for pinealon?

Evidence confidence for pinealon is rated as Low-Moderate. The compound has interesting preclinical data but lacks independent replication, controlled clinical trials, and formal safety evaluation. Most published research originates from a single research network, and the proposed mechanism of action remains incompletely validated.

Is pinealon available as a pharmaceutical?

Pinealon is not approved as a pharmaceutical in any major regulatory jurisdiction. It is not in any Western drug development pipeline and exists primarily as a research compound within the Khavinson bioregulator framework. It should be distinguished from compounds like selank and semax, which have achieved pharmaceutical registration in Russia.

What is the Khavinson bioregulator theory?

The Khavinson bioregulator theory proposes that short peptide sequences (typically 2-4 amino acids) derived from organ-specific tissue extracts can regulate gene expression in corresponding tissues, potentially restoring youthful function in ageing cells. This paradigm has produced multiple compounds including pinealon, epithalon, and others. While internally consistent and supported by the group’s publications, the theory has not been widely adopted by the international research community and requires further independent validation.

References

1. Khavinson V et al. “Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.” Rejuvenation Research, 2011. PubMed
2. Khavinson V et al. “EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease.” Molecules, 2020. PubMed
3. Khavinson V et al. “Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease.” Pharmaceuticals, 2021. PubMed
4. Kraskovskaya NA et al. “Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer’s Disease.” Bull Exp Biol Med, 2017. PubMed
5. Fedoreyeva LI et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry (Mosc), 2011. PubMed
6. Silanteva IA et al. “Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction.” J Phys Chem B, 2019. PubMed
7. Mendzheritsky AM et al. “Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia.” Adv Gerontol, 2015. PubMed
8. Khavinson VK et al. “Peptide Regulation of Gene Expression: A Systematic Review.” Molecules, 2021. PubMed

Dihexa — formally named N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide and also known as PNB-0408 — is a synthetic, metabolically stable analog of angiotensin IV. It was designed by Joseph Harding’s laboratory at Washington State University as part of a programme exploring angiotensin IV derivatives for procognitive applications. Unlike natural angiotensin IV, which is rapidly degraded by peptidases, dihexa was engineered with modifications at both termini to resist enzymatic breakdown.

Key identifiers for the dihexa peptide include CAS number 1401708-83-5, molecular formula C₂₁H₃₃N₃O₄, and molecular weight 395.50 g/mol. It is covered by US Patent 8,673,848. The compound is classified as an HGF mimetic — a molecule that amplifies the activity of hepatocyte growth factor at its c-Met receptor, rather than directly activating the receptor itself.

It is essential to note that dihexa is not approved by the FDA or any regulatory agency for human use. It remains exclusively a research tool, and the published evidence base is extremely limited — consisting primarily of papers from the Harding laboratory at WSU, with minimal independent replication.

Mechanism of Action

The proposed dihexa mechanism centres on potentiation of the dihexa HGF/c-Met signalling pathway rather than direct receptor agonism. According to the originating research, dihexa binds to hepatocyte growth factor and stabilises its dimerisation, facilitating more effective engagement with the c-Met receptor on neurons. This is a fundamentally different approach from conventional neurotrophic peptides like BDNF or NGF, which bind directly to their own receptors.

In the primary research paper (McCoy et al., 2013), dihexa was reported to promote dendritic spine formation (spinogenesis) and dendritic branching in hippocampal neuron cultures. The compound was also reported to facilitate synaptogenesis — the formation of new synaptic connections — through downstream activation of c-Met signalling cascades including PI3K/Akt and MAPK/ERK pathways.

These molecular mechanisms are proposed to underlie dihexa cognitive effects observed in animal models. However, it must be noted that the key mechanistic paper (Benoist et al., 2014; PMID 25187433) linking dihexa’s procognitive effects to HGF/c-Met activation was retracted in 2025 by the Journal of Pharmacology and Experimental Therapeutics, and the original McCoy 2013 paper (PMID 23055539) received a formal expression of concern from the same journal. These retractions significantly weaken confidence in the proposed mechanism.

The HGF/c-Met Pathway

To understand the theoretical basis for dihexa, it helps to examine the HGF/c-Met pathway itself. Hepatocyte growth factor (HGF) — despite its liver-centric name — is expressed widely throughout the central nervous system. It acts through the c-Met receptor (also called MET), a receptor tyrosine kinase involved in cell survival, proliferation, motility, and morphogenesis.

In the brain, HGF/c-Met signalling has been implicated in neuroplasticity, neuronal survival, and synaptic function. Wright and Harding (2011) reviewed the role of the brain renin-angiotensin system and proposed that angiotensin IV’s cognitive effects were mediated through HGF/c-Met rather than traditional angiotensin receptors — a hypothesis that formed the intellectual foundation for dihexa’s development.

Wright and Harding (2015) further elaborated on the brain HGF/c-Met system as a potential therapeutic target for Alzheimer’s disease, arguing that compounds enhancing this pathway could promote neuronal repair and synaptogenesis in neurodegeneration. This remains a theoretical framework that has not been validated in human clinical trials.

Importantly, the HGF/c-Met pathway is also a well-established oncogenic signalling axis. Dysregulated c-Met activation is implicated in tumour growth, invasion, and metastasis across multiple cancer types. This creates a fundamental safety tension: any compound that potentiates HGF/c-Met signalling for neuroprotective purposes may simultaneously carry risks of promoting tumour development. This concern is discussed further in the safety section below. For contrast, neuroprotective peptides like Semax and Selank operate through entirely different mechanisms — primarily BDNF upregulation and GABAergic modulation — without engaging known oncogenic pathways.

Cognitive Enhancement Research

The primary evidence for dihexa as a cognitive enhancer comes from the McCoy et al. (2013) paper, which tested the compound in rats using the scopolamine-induced amnesia model and a bilateral hippocampal-cannulated spatial learning task. The researchers reported that dihexa restored spatial memory performance in scopolamine-treated animals and enhanced learning in normal aged rats when delivered both intracerebroventricularly and — notably — orally.

The claim of oral activity was significant because it suggested the compound could cross the blood-brain barrier, a major practical advantage over larger peptides. The researchers also reported that dihexa was effective at very low doses, which they attributed to its mechanism of potentiating endogenous HGF rather than acting as a direct agonist.

An independent systematic review by Ho and Nation (2018) examined the cognitive benefits of angiotensin IV and related analogs across published experimental studies. While this review covered the broader angiotensin IV field rather than dihexa specifically, it noted that angiotensin IV analogs showed procognitive effects in various memory paradigms. Critically, this review also highlighted the very limited number of research groups studying these compounds and the absence of clinical translation.

Wright and Harding (2019) published a subsequent review in the Journal of Alzheimer’s Disease summarising the brain renin-angiotensin system’s contributions to memory and cognition, including discussion of dihexa’s animal data. This review, however, comes from the same laboratory that developed the compound and does not constitute independent verification.

Alzheimer’s Disease Model Research

The Harding laboratory positioned dihexa as a potential anti-dementia agent, testing it in animal models relevant to Alzheimer’s disease. Wright and Harding (2015) reviewed the theoretical rationale for targeting HGF/c-Met in AD, arguing that deficits in this pathway contribute to synaptic loss — a hallmark of Alzheimer’s pathology that correlates more closely with cognitive decline than amyloid plaque burden.

Wright, Kawas, and Harding (2015) published a broader review in Progress in Neurobiology describing the development of small-molecule angiotensin IV analogs, including dihexa, for treating Alzheimer’s and Parkinson’s diseases. They reported that dihexa reversed cognitive deficits in aged rats and in scopolamine-treated models, framing these results as preclinical proof-of-concept.

However, no Alzheimer’s disease transgenic mouse studies or clinical trials in AD patients have been published. The preclinical data remains confined to pharmacological impairment models (scopolamine) and aged rats — models that have well-documented limitations in predicting clinical efficacy for neurodegenerative diseases. Decades of AD research have shown that compounds effective in these simpler models frequently fail in human trials. Peptides like Cerebrolysin, by comparison, have been tested in human AD patients — though even those results remain debated.

The “10 Million Times More Potent” Claim

Perhaps the most widely circulated claim about dihexa is that it is “ten million times more potent than BDNF” — a statement that requires careful contextualisation to avoid serious misinterpretation.

This claim originates from the McCoy et al. (2013) paper, where the researchers compared the effective concentrations of dihexa and BDNF required to promote dendritic branching in cultured hippocampal neurons. Dihexa reportedly showed activity at picomolar concentrations (10⁻¹² M), while BDNF required nanomolar concentrations (10⁻⁵ M range) — yielding an approximate 10⁷-fold difference in effective concentration for this specific in vitro assay.

Critical caveats that are almost always omitted from popular discussion:

• This is an in vitro comparison only — it reflects dendritic branching in a cell culture dish, not cognitive enhancement in a living organism.
• Dihexa and BDNF work through completely different mechanisms — dihexa potentiates HGF/c-Met while BDNF activates TrkB receptors. Comparing their potencies is like comparing the effective concentration of petrol and an electric charge for starting an engine.
• “More potent” does not mean “more effective” — a lower effective concentration tells you nothing about maximum efficacy, duration of effect, or clinical relevance.
• The comparison has not been independently replicated — it comes from a single experiment in a single paper from the developing laboratory.
• The paper carrying the claim has received a formal expression of concern from the publishing journal.

Responsible interpretation: dihexa appears to promote dendritic branching at much lower concentrations than BDNF in cell culture. Whether this translates to any meaningful cognitive advantage in a living organism — let alone a human — is entirely unknown.

Side Effects & Safety Concerns

There is no human safety data for dihexa. The compound has never been administered to humans in any clinical trial or formal safety study. Any discussion of dihexa side effects must therefore be framed around theoretical risks and the known biology of its target pathway.

The most significant theoretical concern is cancer risk. The HGF/c-Met pathway is one of the most well-characterised oncogenic signalling systems in cancer biology. Aberrant c-Met activation drives tumour growth, angiogenesis, invasion, and metastasis in cancers including lung, gastric, hepatocellular, renal, and breast carcinomas. Major pharmaceutical companies have invested billions in developing c-Met inhibitors as anti-cancer agents. A compound specifically designed to potentiate HGF/c-Met signalling therefore carries an inherent theoretical risk of promoting tumourigenesis, particularly with chronic exposure.

Notably, the Harding laboratory itself published work on HGF mimetics as potential anti-cancer agents (Kawas et al., 2011) — compounds designed to inhibit rather than potentiate c-Met. This illustrates the dual nature of the pathway: the same research group developed both activators (dihexa, for cognition) and inhibitors (for cancer) of the same system. However, this anti-cancer paper (PMID 21859930) was subsequently retracted in 2025.

Additional dihexa side effects concerns include:

• Unknown long-term neurotoxicity — chronic potentiation of any growth factor pathway could have unpredictable effects on neural architecture
• No established dose-response relationship in living organisms beyond limited animal data
• No drug interaction data
• No reproductive toxicity data
• Quality control uncertainty — as an unregulated research chemical, product purity and identity cannot be assumed

The absence of safety data is not evidence of safety. Given the oncogenic potential of its target pathway and the retraction of key supporting papers, the risk-benefit profile of dihexa is highly uncertain.

Pharmacokinetics

Dihexa was specifically engineered for metabolic stability. Unlike natural angiotensin IV (a tetrapeptide rapidly degraded by aminopeptidases), dihexa incorporates protective modifications — an N-terminal hexanoic acid cap and a C-terminal aminohexanoic amide extension — designed to resist enzymatic cleavage.

The McCoy et al. (2013) paper reported that dihexa was orally active in rats, suggesting meaningful absorption from the gastrointestinal tract and penetration across the blood-brain barrier (BBB). If confirmed, this would distinguish it from most peptide-based compounds, which typically require injection or intranasal delivery. However, formal pharmacokinetic parameters — including bioavailability, half-life, volume of distribution, and clearance — have not been published.

The compound’s small size (395.50 g/mol) and relatively lipophilic character are consistent with potential oral absorption and BBB penetration, but the absence of characterised pharmacokinetic data means its half-life remains unknown. No studies have examined dose-response relationships, tissue distribution, or metabolite profiles in any species.

Compound Profile

FAQ

What are the benefits of dihexa?

Proposed dihexa benefits are entirely based on animal and in vitro research. In rat studies, dihexa was reported to enhance spatial memory, reverse scopolamine-induced amnesia, and promote new synaptic connections through HGF/c-Met pathway potentiation. However, no human trials have confirmed any cognitive benefit, and key supporting papers have been retracted or flagged with expressions of concern. Any claimed benefits remain unverified hypotheses.

Is dihexa safe?

There is no human safety data for dihexa. The compound has never undergone clinical trials, formal toxicology assessment, or any regulatory safety review. The most significant theoretical concern is cancer risk, since the HGF/c-Met pathway it potentiates is a well-established oncogenic signalling system. Without safety data, no meaningful risk assessment can be made.

How does dihexa compare to other nootropic peptides?

Dihexa has the weakest evidence base of any commonly discussed nootropic peptide. Unlike Semax (approved in Russia, with multiple clinical studies) or Cerebrolysin (tested in thousands of human subjects), dihexa has never been administered to humans in any published study. Its mechanism — HGF/c-Met potentiation — is also unique among nootropic peptides, which carries both potential novelty and unknown risk.

Is dihexa really 10 million times more potent than BDNF?

This claim refers specifically to the concentration required to promote dendritic branching in hippocampal cell cultures — not to any measure of cognitive enhancement. Dihexa and BDNF act through entirely different receptor systems, making direct potency comparisons largely meaningless. The claim has not been independently replicated, and the paper it originates from has received a formal expression of concern.

Can dihexa be taken orally?

Animal studies reported oral activity for dihexa in rats, suggesting it may cross the blood-brain barrier when taken by mouth. However, formal pharmacokinetic data has not been published, and oral bioavailability has not been quantified. These are preliminary observations in rodents, not established pharmacological parameters.

What is PNB-0408?

PNB-0408 is the research designation for dihexa. The name derives from its development at the Pacific Northwest Biotechnology laboratory (the Harding lab’s commercial entity). The compound’s full chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, with CAS number 1401708-83-5.

Why have dihexa papers been retracted?

Several papers from the Harding laboratory have been retracted or flagged by the Journal of Pharmacology and Experimental Therapeutics. The Benoist et al. (2014) paper on dihexa’s procognitive and synaptogenic effects was retracted in 2025, and the McCoy et al. (2013) foundational paper received a formal expression of concern. Related papers on angiotensin IV analogs from the same group have also been retracted. These actions significantly undermine confidence in the published dihexa evidence base.

Is dihexa FDA approved?

No. Dihexa is not approved by the FDA, EMA, or any regulatory agency worldwide. It has never entered clinical trials in humans. It remains an early-stage research compound with no path to regulatory approval currently visible in the published literature.

References

1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. doi:10.1124/jpet.112.199497. PMID: 23055539. [Expression of concern issued]
2. Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014;351(2):390-402. doi:10.1124/jpet.114.218735. PMID: 25187433. [Retracted 2025]
3. Wright JW, Harding JW. Brain renin-angiotensin—a new look at an old system. Prog Neurobiol. 2011;95(1):49-67. doi:10.1016/j.pneurobio.2011.07.001. PMID: 21777652.
4. Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):985-1000. doi:10.3233/JAD-142814. PMID: 25649658.
5. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015;125:26-46. doi:10.1016/j.pneurobio.2014.11.004. PMID: 25455861.
6. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): a systematic review of experimental studies. Neurosci Biobehav Rev. 2018;92:209-225. doi:10.1016/j.neubiorev.2018.05.005. PMID: 29733881.
7. Wright JW, Harding JW. Contributions by the brain renin-angiotensin system to memory, cognition, and Alzheimer’s disease. J Alzheimers Dis. 2019;67(2):469-480. doi:10.3233/JAD-181035. PMID: 30664507.

DSIP — delta sleep-inducing peptide — is a naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. First isolated from rabbit cerebral venous blood in 1977 by Schoenenberger and Monnier at the University of Basel, the DSIP peptide was originally identified for its ability to promote delta-wave (slow-wave) activity on EEG recordings during sleep.[1] The name “delta sleep-inducing peptide” has endured, though it is somewhat misleading — subsequent research revealed DSIP to be a broad-spectrum neuromodulator rather than a simple sleep switch.

What is DSIP in practical terms? It is an endogenous neuropeptide that modulates multiple physiological systems simultaneously: sleep architecture, stress response, pain perception, circadian rhythm, and certain endocrine pathways.[1][2] This wide-ranging modulatory profile distinguishes DSIP from targeted receptor agonists like ipamorelin or PT-141, which operate through well-characterised single-receptor mechanisms. DSIP’s mechanism, by contrast, remains incompletely understood — no confirmed receptor has been identified, which is highly unusual for a bioactive peptide with documented physiological effects.

Sometimes referred to as a “delta sleep peptide” or even — incorrectly — as a “deep sleep inducing peptide,” DSIP occupies a unique and somewhat enigmatic position in neuropeptide research. Its evidence base is dominated by studies from the 1980s and 1990s, with relatively little modern investigation. This page examines the available research honestly, including the significant limitations that define the current state of DSIP science.

Compound Profile

How DSIP Was Discovered

The story of the delta sleep-inducing peptide begins in the 1960s when Swiss researchers Schoenenberger and Monnier began investigating humoral sleep factors — substances circulating in the blood that might promote sleep. By 1977, they had isolated a nonapeptide from the cerebral venous blood of rabbits that had been electrically stimulated to sleep, and demonstrated that this substance could induce delta-wave EEG patterns when transferred to recipient animals.[1]

Graf and Kastin published the first comprehensive review of DSIP in 1984, documenting its effects on sleep in rabbits, rats, mice, cats, and humans.[1] Their 1986 update noted an expanding research scope — beyond sleep, DSIP was showing effects on pain, withdrawal symptoms, hormonal regulation, and stress responses.[2] By the late 1980s, DSIP research had broadened considerably, but a fundamental problem persisted: no one could identify the gene encoding DSIP or isolate a specific receptor for it.[3]

Kovalzon and Strekalova’s 2006 review, pointedly titled “DSIP: A Still Unresolved Riddle,” summarised three decades of confusion. They noted that the link between DSIP and sleep had never been fully characterised, in part because of the failure to identify the DSIP gene, protein precursor, or receptor.[3] This review remains one of the most honest assessments of DSIP’s scientific status — a peptide with documented biological activity but no confirmed molecular target.

Sleep Architecture Research

The original and most well-known area of DSIP research is its relationship with sleep. Schneider-Helmert and Schoenenberger (1981) conducted one of the few human clinical studies, testing synthetic DSIP in six chronic insomniacs. They reported longer sleep duration, higher sleep quality with fewer interruptions, and slightly more REM sleep — with no daytime sedation or other side effects.[4] Notably, the sleep-promoting effect appeared only in the second hour following administration, with a slight arousing effect in the first hour. The researchers concluded that DSIP has a “normalising influence on human sleep regulation” rather than acting as a sedative.[4]

This is an important distinction for understanding DSIP sleep research: the peptide does not simply knock subjects out. Instead, the available data suggests it may help regulate and normalise disrupted sleep patterns — a modulatory rather than sedative function. As a sleep peptide, DSIP appears to influence sleep architecture without the cognitive impairment or dependence associated with conventional sedative-hypnotics. However, this evidence comes from very small studies conducted decades ago, and the characterisation of DSIP as a “sleep peptide” should be treated with appropriate caution.

Blood-Brain Barrier Crossing

One of the more surprising findings about DSIP is its ability to cross the blood-brain barrier (BBB) — unusual for a peptide of its size. Zlokovic et al. (1989) demonstrated a saturable, high-affinity transport mechanism for DSIP at the BBB in guinea pig models.[5] Their study showed that DSIP uptake was inhibited by unlabelled DSIP and by L-tryptophan (DSIP’s N-terminal residue), suggesting a specific carrier-mediated transport process rather than passive diffusion.

This finding has implications for understanding how peripherally circulating DSIP could exert central nervous system effects. The saturable transport mechanism distinguishes DSIP from most peptides, which are largely excluded from the brain by the BBB. It also provides a potential explanation for DSIP’s wide-ranging neuromodulatory effects — if the peptide can access the CNS efficiently, its modulatory actions on sleep, stress, and endocrine pathways become more plausible.

Stress Response and Neuroendocrine Effects

Beyond sleep, DSIP research has revealed potential roles in stress modulation and endocrine regulation. Graf and Kastin’s 1986 review documented evidence that DSIP influences ACTH and cortisol dynamics — key components of the hypothalamic-pituitary-adrenal (HPA) axis that governs the stress response.[2] Some animal studies suggested that DSIP could normalise stress-disrupted physiological parameters, leading to its characterisation as a “stress-protective” peptide.

Sahu and Kalra (1987) demonstrated that DSIP stimulates luteinising hormone (LH) release in steroid-primed ovariectomised rats, suggesting a connection between this sleep peptide and hypothalamic neural circuits involved in reproductive hormone regulation.[6] This finding aligns with the broader picture of DSIP as a neuromodulator that interfaces with multiple endocrine pathways rather than a single-function sleep factor. The endocrine effects of DSIP contrast with the targeted hormonal approaches of peptides like kisspeptin or gonadorelin, which act through well-defined receptor-mediated pathways on the reproductive axis.

Recovery & Sleep Context

DSIP’s primary research relevance lies in recovery and sleep — the domain for which it was originally named. The limited human data suggests a normalising effect on disrupted sleep patterns rather than a simple hypnotic action.[4] In animal models, DSIP has been associated with increased slow-wave sleep, which is the sleep phase most closely linked to physical recovery, immune function, and growth hormone secretion.

The theoretical appeal of a sleep peptide that modulates sleep architecture without sedation or dependence is considerable, particularly in the context of recovery and sleep optimisation. However, the evidence base is thin by modern standards — the key human study involved only six participants,[4] and most animal studies predate current methodological standards. This positions DSIP as an interesting but inadequately validated compound within the recovery and sleep research landscape, lacking the robust clinical evidence that characterises peptides like semaglutide or tirzepatide in their respective domains.

Neuroprotection Context

Recent research has explored DSIP’s potential neuroprotective properties. Tukhovskaya et al. (2021) investigated DSIP in a rat model of focal stroke (middle cerebral artery occlusion), finding that nasally administered DSIP led to accelerated recovery of motor functions, though brain infarction volume differences did not reach statistical significance.[7] This is one of the few modern studies to investigate DSIP and provides tentative evidence of neuroprotective potential in an ischaemic context.

Earlier research documented antioxidant and free-radical scavenging properties for DSIP, which could contribute to a neuroprotective profile.[2] The peptide’s stress-protective characteristics — including modulation of HPA axis activity — may also confer indirect neuroprotective benefit by reducing cortisol-mediated neuronal damage. These neuroprotective pathways differ from those of cerebrolysin, which acts through direct neurotrophic factor activity, and semax, which operates via melanocortin-derived mechanisms.

DSIP Benefits

The potential DSIP benefits identified across the available research include:

• Sleep normalisation without sedation: Human studies suggest DSIP may improve sleep quality and duration without the daytime sedation, cognitive impairment, or dependence associated with conventional hypnotics.[4]
• Stress modulation: Animal studies indicate potential normalisation of stress-disrupted physiology, including modulation of ACTH and cortisol dynamics.[2]
• Blood-brain barrier crossing: Unlike most peptides, DSIP crosses the BBB via a saturable transport mechanism, enabling central nervous system effects following peripheral exposure.[5]
• Neuroendocrine modulation: Evidence of effects on LH and potentially GH secretion patterns suggests broader endocrine modulatory activity.[6]
• Potential neuroprotection: Preliminary evidence of motor function recovery following stroke and antioxidant properties.[7]
• Anti-seizure properties: DSIP and its tetrapeptide analogue have shown anti-convulsant effects in animal seizure models.[2]

It is essential to note that these DSIP benefits are derived primarily from animal studies and very small human trials conducted decades ago. The evidence confidence for DSIP is limited — considerably weaker than for most peptides featured on this site.

DSIP Side Effects

The DSIP side effects profile is difficult to characterise comprehensively due to the limited clinical data available:

• No significant adverse effects reported: In the small human sleep study by Schneider-Helmert and Schoenenberger, no side effects were documented — no daytime sedation, no cognitive impairment, no withdrawal.[4]
• Transient initial arousal: An initial slight arousing effect was observed in the first hour after administration before sleep-promoting effects emerged.[4]
• Extremely limited safety data: With only a handful of human studies involving very small numbers of participants, the full DSIP side effects spectrum is essentially unknown.
• No long-term safety data: No studies have evaluated long-term effects of DSIP exposure in humans.

The absence of reported adverse effects should not be interpreted as evidence of safety. It more likely reflects the extremely limited scope of human studies. Compared to compounds like liraglutide or semaglutide, where thousands of participants in large RCTs have generated comprehensive safety profiles, the DSIP safety dataset is essentially non-existent by modern standards.

The Missing Receptor Problem

Perhaps the most significant scientific limitation of DSIP is the absence of an identified receptor. For a bioactive peptide with documented physiological effects, this is highly unusual. Virtually all well-characterised peptides — from GH-releasing peptides like GHRP-2 and GHRP-6 to neuropeptides like selank — operate through identified receptor systems. DSIP does not.

Kovalzon and Strekalova (2006) highlighted this as the central unresolved problem in DSIP research, noting that the failure to identify a DSIP gene, protein precursor, or receptor has fundamentally limited the field.[3] Without a known receptor, it is impossible to fully characterise DSIP’s mechanism of action, predict its effects with confidence, or develop structure-activity relationships for potential therapeutic optimisation. This “missing receptor” problem should be front-of-mind when evaluating any claims about DSIP’s biological activity.

Limits of Current Evidence

• Dated evidence base: The majority of DSIP research was conducted between 1977 and the mid-1990s. Modern methodological standards, statistical approaches, and reproducibility requirements were not consistently applied.
• Extremely small human studies: The key clinical study involved only six participants.[4] This is insufficient to draw reliable conclusions about efficacy or safety.
• No confirmed receptor or gene: The absence of an identified molecular target fundamentally limits mechanistic understanding and is unusual for a purportedly bioactive peptide.[3]
• No regulatory approval anywhere: Unlike selank (approved in Russia) or tesamorelin (FDA-approved), DSIP has achieved no regulatory validation in any jurisdiction.
• Limited modern replication: Very few contemporary studies have revisited DSIP’s core claims. The 2021 stroke recovery study is a rare modern exception.[7]
• Potential endogeneity questions: The 2006 Kovalzon review raised the possibility that the observed biological activity might involve DSIP-like peptides rather than DSIP itself — further complicating interpretation.[3]
• Not FDA approved: DSIP is a research compound only with no approved clinical indications.

DSIP Peptide UK Research Availability

The DSIP peptide is available through research chemical suppliers in the UK and internationally. As with all research peptides, DSIP UK availability is limited to legitimate research purposes. The compound is not a controlled substance, but it has no approved medical indications anywhere in the world. UK-based researchers investigating this DSIP peptide UK compound should note that the absence of regulatory approval reflects the limited and dated evidence base rather than specific safety concerns.

Verdict

This DSIP review of the available evidence reveals a genuinely unusual compound — a naturally occurring nonapeptide with documented neuromodulatory effects but no confirmed receptor, no identified gene, and an evidence base that peaked in the 1980s. The DSIP peptide was named for its ability to induce delta sleep, but subsequent research revealed a neuromodulator with effects spanning sleep architecture, stress physiology, endocrine regulation, and neuroprotection.[1][2][3]

The honest assessment is that DSIP remains, as Kovalzon and Strekalova described it in 2006, “a still unresolved riddle.”[3] The small human sleep study from 1981 showed encouraging results — normalised sleep without sedation or side effects — but six participants do not constitute robust evidence.[4] The blood-brain barrier transport data is genuinely interesting and methodologically sound.[5] The neuroprotective findings from 2021 provide a rare modern data point.[7] But the overall evidence confidence is limited.

DSIP should be viewed as a scientifically interesting but inadequately validated research compound. Its appeal lies in the concept — an endogenous sleep peptide that normalises rather than sedates — but the evidence does not yet support confident conclusions about its effects, mechanisms, or safety profile. Researchers interested in DSIP should approach it with appropriate scientific caution and an awareness that the foundational questions about this peptide remain unanswered after nearly five decades of intermittent investigation.

FAQ

What is DSIP?

DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide first isolated from rabbit brain tissue in 1977. With the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, it was originally characterised for its ability to promote delta-wave sleep patterns. Subsequent research revealed it to be a broad neuromodulator affecting sleep, stress response, pain perception, and endocrine function — though its precise mechanism remains unknown due to the absence of an identified receptor.[1][3]

Does DSIP actually improve sleep?

A small 1981 clinical study in six chronic insomniacs showed that DSIP improved sleep duration and quality without sedation or side effects.[4] However, this study is extremely small by modern standards. Animal studies have shown delta-wave promoting effects, but the evidence base for DSIP sleep effects in humans is limited and dated.

Is DSIP safe?

The available human data — limited to very small studies — reported no significant adverse effects.[4] However, the absence of reported side effects reflects the extremely limited scope of clinical investigation rather than confirmed safety. No long-term safety data exists for DSIP in humans.

Why hasn’t DSIP been developed as a medicine?

The failure to identify a DSIP receptor, gene, or protein precursor has fundamentally stalled pharmaceutical development. Without understanding the molecular target, drug development is effectively impossible. The dated and limited evidence base has also discouraged modern pharmaceutical investment.[3]

How does DSIP cross the blood-brain barrier?

Unlike most peptides, DSIP crosses the blood-brain barrier via a saturable, carrier-mediated transport mechanism. This was demonstrated by Zlokovic et al. (1989) in guinea pig models, suggesting a specific active transport process rather than passive diffusion.[5]

Is DSIP the same as melatonin?

No. DSIP and melatonin are entirely different molecules with distinct mechanisms. Melatonin is a hormone produced by the pineal gland with a well-characterised receptor system and established role in circadian rhythm regulation. DSIP is a neuropeptide with no confirmed receptor and a much broader (though less well-understood) neuromodulatory profile.

Is DSIP approved by the FDA?

No. DSIP is not approved by the FDA, EMA, or any other regulatory body worldwide. It has no approved medical indications in any jurisdiction. Unlike peptides such as semaglutide or tesamorelin, which have undergone rigorous regulatory review, DSIP remains a research-only compound.

References

1. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93. PMID: 6145137
2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. PMID: 3550726
3. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. PMID: 16539679
4. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981;37(9):913-917. PMID: 7028502
5. Zlokovic BV, et al. Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. Peptides. 1989;10(2):249-254. PMID: 2547200
6. Sahu A, Kalra SP. Delta sleep-inducing peptide (DSIP) stimulates LH release in steroid-primed ovariectomized rats. Life Sci. 1987;40(12):1201-1206. PMID: 3550343
7. Tukhovskaya EA, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173. PMID: 34500605

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. DSIP is not approved by the FDA or any regulatory body for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.

Cerebrolysin (FPF-1070) is not a single peptide but a standardised mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue through controlled enzymatic proteolysis. The cerebrolysin peptide preparation is manufactured by EVER Neuro Pharma (Austria) and represents one of the most extensively studied neurotrophic preparations in clinical medicine — a biological product rather than a synthetic compound. Unlike single-peptide research compounds such as Selank or GHK-Cu, cerebrolysin delivers a complex cocktail of peptide fragments with neurotrophic factor-like activity, including BDNF-like, GDNF-like, and CNTF-like components.

Cerebrolysin is approved in over 30 countries across Europe, Asia, and Latin America for neurological conditions including ischaemic stroke recovery, traumatic brain injury (TBI), and various forms of dementia. It is not approved by the FDA or MHRA and remains research-use-only in the United States and United Kingdom. Despite this regulatory gap, cerebrolysin has accumulated one of the largest clinical evidence bases of any neurotrophic preparation, including multiple Cochrane systematic reviews.

The distinction between cerebrolysin and most peptides on this site is important: where compounds like BPC-157 or TB-500 are defined single-sequence peptides, the cerebrolysin peptide preparation is a biological product containing hundreds of peptide fragments acting through multiple neurotrophic pathways simultaneously.

Compound Profile

What Does Cerebrolysin Actually Do?

Cerebrolysin delivers a cocktail of neurotrophic peptide fragments that mimic endogenous brain growth factors — specifically brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). It provides small protein fragments that the brain normally produces to support neuronal survival, maintain synaptic connections, and promote new neural pathways. The preparation’s peptide components (all under 10 kDa) are designed to cross the blood-brain barrier.

The multi-target approach distinguishes cerebrolysin from single-peptide compounds. Where sermorelin acts through one receptor system, cerebrolysin simultaneously engages multiple neurotrophic signalling cascades — potentially advantageous for complex neurological conditions where damage spans multiple cellular pathways.

Clinical research has centred on three primary contexts: recovery after ischaemic stroke, neuroprotection following traumatic brain injury, and cognitive support in vascular dementia and Alzheimer’s disease. The evidence base includes randomised controlled trials, observational studies, and multiple Cochrane systematic reviews providing independent assessment of evidence quality.

How Cerebrolysin Works

Cerebrolysin’s mechanism of action operates through neurotrophic factor mimicry. The preparation contains peptide fragments that activate the same downstream signalling pathways as endogenous neurotrophic factors — principally the BDNF/TrkB, GDNF/GFRα, and CNTF/CNTFRα receptor systems. Rejdak et al. (2023) provided a comprehensive analysis of how cerebrolysin modulates neurotrophic factor expression in the context of dementia, stroke, and TBI, demonstrating that the compound influences multiple neurotrophic cascades simultaneously rather than targeting a single pathway.[1] This multi-pathway engagement explains the breadth of clinical conditions in which cerebrolysin has been studied.

At the cellular level, cerebrolysin promotes neuronal survival through anti-apoptotic signalling, supports synaptic plasticity by enhancing long-term potentiation mechanisms, and stimulates neurogenesis — the formation of new neurons from neural stem cells. Fiani et al. (2021) reviewed the comprehensive literature on cerebrolysin’s mechanisms across stroke, neurodegeneration, and traumatic brain injury, noting consistent signals for neuroprotective and neuroregenerative activity across diverse experimental models.[2] The biological rationale is that damaged or degenerating neural tissue requires neurotrophic support, and cerebrolysin provides this through a preparation that mimics the brain’s own growth factor repertoire.

The multi-target nature creates both advantages and interpretive challenges. Complex neurological injuries affect multiple cell types and pathways, and a multi-target intervention matches this complexity. However, attributing observed clinical effects to specific mechanisms is more difficult with a mixture than with a defined single compound like ipamorelin or GHK-Cu, where structure-activity relationships are clearer.

Neuroprotection Context

Neuroprotection represents the primary research domain for cerebrolysin, with the strongest clinical evidence base concentrated in ischaemic stroke and traumatic brain injury. The cerebrolysin stroke research literature is particularly extensive, spanning multiple randomised controlled trials and Cochrane-level systematic review. Cook et al. (2025) included cerebrolysin in their updated review of neuroprotective strategies after traumatic brain injury, recognising its position within the broader landscape of agents studied for post-TBI neuroprotection.[3]

The Cochrane systematic review by Ziganshina et al. (2023) represents the most rigorous independent evaluation of cerebrolysin for acute ischaemic stroke. The review concluded that the evidence for clinical benefit remained uncertain — while some trials showed positive signals on surrogate endpoints, the overall evidence quality was limited by methodological concerns and inconsistent outcome reporting.[4] This Cochrane assessment does not conclude that cerebrolysin is ineffective, but rather that available evidence does not yet provide certainty about meaningful clinical benefit. Similarly, cerebrolysin TBI research has shown promising preclinical and clinical signals, though definitive evidence of efficacy remains under investigation.

Mureșanu et al. (2022) offered a more favourable assessment, presenting clinical trial data demonstrating improvements in neurological outcomes and functional recovery.[5] The neuroprotection evidence for cerebrolysin is therefore characterised by a tension between positive individual trial results and cautious systematic review conclusions. Homberg et al. (2025) further demonstrated cerebrolysin’s potential in a randomised pilot study showing enhanced recovery of nonfluent aphasia after acute ischaemic stroke when combined with speech therapy.[8]

Cognitive & Nootropic Support Context

Cognitive and nootropic support represents the second major research domain for cerebrolysin, primarily through studies in vascular dementia and Alzheimer’s disease. The cerebrolysin nootropic research interest stems from its neurotrophic factor mimicry: BDNF and GDNF are critically involved in synaptic plasticity, memory consolidation, and maintenance of cholinergic neurons progressively lost in dementia — providing a mechanistic basis for cerebrolysin’s relevance.

The Cochrane systematic review by Cui et al. (2019) evaluated cerebrolysin for vascular dementia and found possible benefit on cognitive outcomes, though evidence was rated as low-certainty.[6] While some trials showed improvements on cognitive assessment scales, clinical significance was uncertain and overall evidence quality was limited by small sample sizes and risk of bias.

Wang et al. (2024) conducted a network meta-analysis comparing neuroprotective agents for improving neurological function in acute ischaemic stroke, providing comparative context for cerebrolysin.[7] For the cognitive and nootropic support evidence landscape, cerebrolysin’s position is notable — few neurotrophic preparations have been subjected to Cochrane-level systematic review for cognitive outcomes.

Cerebrolysin Benefits

The research-documented cerebrolysin benefits should be interpreted within the context of the available evidence, including both supportive trial data and the more cautious conclusions of Cochrane systematic reviews:

• Multi-pathway neurotrophic support: cerebrolysin delivers peptide fragments mimicking multiple endogenous neurotrophic factors (BDNF, GDNF, CNTF), engaging several neuroprotective signalling cascades simultaneously.[1]
• Extensive clinical evidence base: one of the most studied neurotrophic preparations globally, with randomised controlled trials across stroke, TBI, and dementia populations — a substantially larger clinical dataset than most peptide research compounds.
• Regulatory approval in 30+ countries: approved for clinical use in neurological conditions across Europe, Asia, and Latin America, providing real-world usage data alongside controlled trial evidence.
• Multiple Cochrane systematic reviews: subjected to independent systematic review for both acute ischaemic stroke and vascular dementia — an unusual level of evidence scrutiny for a neurotrophic preparation.[4][6]
• Studied across multiple neurological conditions: ischaemic stroke, traumatic brain injury, vascular dementia, Alzheimer’s disease, and post-stroke aphasia recovery.[8]
• Standardised manufacturing process: produced through controlled enzymatic proteolysis of porcine brain tissue with defined quality parameters, providing batch-to-batch consistency for a biological preparation.

Cerebrolysin Side Effects

The clinical trial literature generally reports a favourable cerebrolysin side effects profile. Across multiple randomised controlled trials, cerebrolysin has been associated with mild and transient adverse effects:

• Common reported effects: dizziness, headache, and injection site reactions.
• Uncommon reported effects: agitation, insomnia, nausea — observed at low frequency.
• Biological product considerations: as a porcine-derived preparation, theoretical immunogenicity concerns exist, though clinically significant allergic reactions have been rarely reported.
• Cochrane safety assessment: both Cochrane reviews noted a generally acceptable safety profile with no major safety signals.[4][6]

The safety data should be contextualised by the same methodological limitations affecting the efficacy evidence. As a biological product, cerebrolysin carries inherent quality considerations that differ from synthetic peptides like CJC-1295 or GHRP-2.

Half-Life

The concept of half-life does not apply to cerebrolysin in the conventional pharmacokinetic sense. Unlike a defined single compound — for example, semaglutide with its well-characterised 168-hour half-life — cerebrolysin is a complex mixture of hundreds of peptide fragments and free amino acids, each with potentially different absorption, distribution, metabolism, and elimination profiles.

The biological activity of cerebrolysin is mediated through neurotrophic signalling cascades that extend well beyond the plasma clearance window of individual peptide components. Once the peptide fragments engage their respective receptor systems (TrkB, GFRα, CNTFRα), the downstream intracellular signalling — including gene expression changes, protein synthesis, and synaptic remodelling — continues for hours to days. This is consistent with the general pharmacology of neurotrophic factors, where the signalling event is brief but the biological response is sustained through transcriptional and structural changes.

Limits of Current Evidence

This section is essential for responsible interpretation of the cerebrolysin evidence base. Despite a large body of clinical research, significant limitations exist that should inform any assessment of the compound:

• Not FDA approved: cerebrolysin has not received approval from the FDA or MHRA. Cerebrolysin UK availability is limited to research-use-only status, as the MHRA has not licensed it for clinical use. Its approval in 30+ countries reflects different regulatory standards and evidence thresholds across jurisdictions.
• Cochrane review conclusions are cautious: the Cochrane review for acute ischaemic stroke (Ziganshina et al. 2023) found uncertain evidence of clinical benefit, while the vascular dementia review (Cui et al. 2019) rated the evidence as low-certainty.[4][6] These independent assessments temper the positive signals from individual trials.
• Geographic concentration of positive trials: many of the most positive RCTs were conducted in countries where cerebrolysin is already approved and commercially available, introducing potential bias in study design, conduct, and interpretation.
• Heterogeneous trial designs: outcome measures, treatment durations, severity populations, and comparator conditions vary substantially across the literature.
• Biological product variability: while manufacturing is standardised, batch-to-batch composition may vary within defined parameters — a concern that does not apply to synthetic peptides like epithalon or Pal-GHK.
• Mechanism attribution: because cerebrolysin contains hundreds of peptide fragments, attributing clinical effects to specific molecular components is extremely difficult.
• No consensus on optimal indications: despite decades of research, no definitive consensus exists on which patient populations benefit most.

Verdict

Cerebrolysin occupies a unique and somewhat paradoxical position in the neurotrophic peptide landscape. It is the most clinically studied multi-peptide neurotrophic preparation in existence, with approval in over 30 countries and scrutiny from multiple Cochrane systematic reviews. Any comprehensive cerebrolysin review of the evidence base must acknowledge that it includes randomised controlled trials across stroke, TBI, and dementia populations — a breadth unusual in this field.

Yet the conclusions remain uncertain. The Cochrane reviews — the gold standard for evidence synthesis — found uncertain benefit for ischaemic stroke and low-certainty evidence for vascular dementia. This disconnect between volume of research and certainty of conclusions reflects genuine challenges in neurotrophic agent research: heterogeneous trial designs, variable outcome measures, and the inherent difficulty of demonstrating clear clinical benefit in complex neurological conditions.

The multi-target approach through neurotrophic factor mimicry is pharmacologically rational for conditions involving multi-pathway neuronal damage. However, the mixed Cochrane findings and absence of FDA or MHRA approval mean that researchers should interpret the evidence cautiously. For the broader context of neuroprotection and cognitive support research, cerebrolysin serves as an important reference point — demonstrating both the potential and the evidentiary challenges of neurotrophic peptide interventions. Related research compounds include Selank for neuropeptide-based approaches, and GHK-Cu for peptide-mediated tissue support.

FAQ

What is Cerebrolysin?

Cerebrolysin is a standardised preparation of low-molecular-weight neuropeptides and free amino acids derived from porcine (pig) brain tissue. It is not a single synthetic peptide but a biological mixture manufactured by EVER Neuro Pharma (Austria). It contains peptide fragments with neurotrophic factor-like activity — mimicking the brain’s own growth factors — and is one of the most clinically studied neurotrophic preparations globally.[1][2]

Is Cerebrolysin FDA approved?

No. Cerebrolysin is not approved by the FDA (United States) or MHRA (United Kingdom). It is approved in over 30 countries across Europe, Asia, and Latin America for neurological conditions including stroke recovery, traumatic brain injury, and dementia. In the US and UK, it is classified as a research-use-only compound.

What conditions is Cerebrolysin studied for?

Cerebrolysin has been studied primarily for ischaemic stroke recovery, traumatic brain injury (TBI), vascular dementia, and Alzheimer’s disease. The clinical evidence includes randomised controlled trials across these indications, as well as Cochrane systematic reviews for acute ischaemic stroke and vascular dementia.[4][6] More recent research has also explored its potential in post-stroke aphasia recovery.[8]

Is Cerebrolysin a single peptide?

No. Cerebrolysin is a complex biological mixture containing hundreds of low-molecular-weight peptide fragments (all under 10 kDa) plus free amino acids. It is produced through standardised enzymatic proteolysis of porcine brain tissue. This distinguishes it from defined single-sequence peptides like BPC-157 or TB-500.

What do Cochrane reviews say about Cerebrolysin?

Two Cochrane systematic reviews have evaluated cerebrolysin. Ziganshina et al. (2023) reviewed cerebrolysin for acute ischaemic stroke and found the evidence for clinical benefit to be uncertain.[4] Cui et al. (2019) reviewed cerebrolysin for vascular dementia and found possible benefit on cognitive outcomes, though the evidence was rated as low-certainty.[6] Both reviews noted methodological concerns across the included trials.

Is Cerebrolysin available in the UK?

Cerebrolysin is not approved or commercially available for clinical use in the United Kingdom. Cerebrolysin UK status remains research-use-only, as it is not licensed by the MHRA. In the UK context, it is considered a research compound. It is approved and commercially available in over 30 other countries, predominantly in continental Europe, Asia, and Latin America.

How does Cerebrolysin differ from other neurotrophic compounds?

Cerebrolysin is unique in being a multi-peptide biological preparation rather than a single synthetic compound. While peptides like Selank and Gonadorelin are defined synthetic neuropeptides with specific molecular targets, cerebrolysin contains a complex mixture of peptide fragments that simultaneously mimic multiple endogenous neurotrophic factors (BDNF, GDNF, CNTF). This multi-target approach is pharmacologically distinct and means that cerebrolysin’s effects cannot be attributed to a single mechanism.[1]

References

1. Rejdak K, et al. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. PMID: 37052231
2. Fiani B, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurol Sci. 2021;42(4):1345-1353. PMID: 33515100
3. Cook AM, et al. Update on Neuroprotection after Traumatic Brain Injury. CNS Drugs. 2025;39(5):443-462. PMID: 40087248
4. Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10:CD007026. PMID: 37818733
5. Mureșanu DF, et al. Role and Impact of Cerebrolysin for Ischemic Stroke Care. J Clin Med. 2022;11(5):1273. PMID: 35268364
6. Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;11:CD008900. PMID: 31710397
7. Wang Y, et al. Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis. Front Neurosci. 2024;18:1507034. PMID: 39834702
8. Homberg V, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025;56(4):1053-1061. PMID: 39957612

Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone (ACTH) responsible for cognitive and neurotrophic effects, stripped of the hormonal segments that drive adrenal cortex activation. The semax peptide was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, with the specific goal of isolating nootropic and neuroprotective activity from full-length ACTH while eliminating cortisol-stimulating properties. Its sequence — Met-Glu-His-Phe-Pro-Gly-Pro — retains the ACTH(4-10) core with a C-terminal Pro-Gly-Pro extension engineered for metabolic stability.

What distinguishes semax from most investigational peptides is its regulatory history: it has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray, giving it a level of clinical validation that most research peptides lack. Semax nootropic research centres on its ability to upregulate brain-derived neurotrophic factor (BDNF) and activate dopaminergic and serotonergic systems — mechanisms that connect it to synaptic plasticity, learning, memory, and neuroprotection after ischemic injury.

Despite its Russian approval and a growing body of English-language mechanistic research, semax remains unapproved by the FDA and EMA. It occupies an unusual position: more clinically validated than most research peptides, but without the large-scale Western clinical trial data that would establish it in international regulatory frameworks. For context, compounds like BPC-157 and GHK-Cu share investigational neuroprotective profiles through different mechanisms.

Compound Profile

What Does Semax Actually Do?

Semax enhances cognitive function primarily through upregulation of brain-derived neurotrophic factor (semax BDNF). BDNF is the brain’s principal neurotrophin — the protein that drives synaptic plasticity, neuronal survival, and the formation of new synaptic connections that underlie learning and memory. By increasing BDNF and its receptor TrkB in the hippocampus, semax activates the molecular machinery of cognitive enhancement at its most fundamental level.[1] This positions it as one of the most mechanistically rational semax nootropic compounds in the research peptide space.

Beyond BDNF, semax activates dopaminergic and serotonergic neurotransmitter systems — the two pathways most directly associated with motivation, focus, mood regulation, and reward processing.[2] This dual neurotransmitter modulation, combined with neurotrophic factor upregulation, creates a multi-mechanism cognitive support profile. Crucially, despite being derived from ACTH, semax does not stimulate cortisol or activate the adrenal cortex — the hormonal segments responsible for ACTH’s stress-hormone effects are absent from the ACTH(4-10) fragment.

The second major research domain is semax neuroprotective activity. Preclinical studies demonstrate that semax activates neurotrophic gene transcription after cerebral ischemia — the oxygen-deprived conditions of stroke.[3] This neuroprotective profile has driven its clinical use in Russia for both cognitive support and ischemic stroke recovery. Semax operates through a fundamentally different mechanism than tissue-repair peptides like BPC-157 or TB-500, targeting neurotrophin expression rather than angiogenesis or inflammation.

How Semax Works

The pharmacological logic of semax begins with the structure of ACTH itself. Full-length ACTH (39 amino acids) drives cortisol production through the adrenal cortex — but the cognitive and neurotrophic effects reside specifically in the ACTH 4-10 fragment (positions 4 through 10 of the ACTH sequence). By isolating this fragment and discarding the N-terminal (1-3) and C-terminal (11-39) segments, semax retains the cognitive-active region while eliminating hormonal activity entirely. The C-terminal Pro-Gly-Pro extension was engineered to prevent rapid enzymatic degradation, extending the functional half-life of what would otherwise be a rapidly cleared peptide fragment.

Dolotov et al. (2006) demonstrated that semax regulates BDNF and TrkB expression in the rat hippocampus — providing direct evidence that the ACTH 4-10 fragment drives neurotrophic signalling in the brain region most critical for memory and learning.[1] Eremin et al. (2005) established that semax activates both dopaminergic and serotonergic brain systems in rodents, identifying the neurotransmitter pathways that complement its neurotrophic activity.[2] Dmitrieva et al. (2010) extended the mechanistic picture to neuroprotection, showing that semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia — demonstrating that the compound upregulates the brain’s own repair machinery in response to ischemic injury.[3]

This mechanism — neurotrophic factor upregulation combined with neurotransmitter system activation — is distinct from most other peptide mechanisms. Where growth hormone secretagogues like ipamorelin and GHRP-2 operate through the GH-IGF-1 axis, and tissue-repair peptides like TB-500 work through actin regulation, semax acts directly on central nervous system neurotrophin pathways.

Cognitive & Nootropic Support Context

The cognitive and nootropic support profile of semax is its primary research domain — and the area where the mechanistic evidence is strongest. BDNF upregulation is the central mechanism: brain-derived neurotrophic factor drives long-term potentiation (LTP), the cellular process underlying memory consolidation and learning. By increasing both BDNF and its receptor TrkB in the hippocampus, semax activates the molecular substrate of cognitive enhancement at a foundational level.[1]

Manchenko et al. (2010) characterised nootropic and analgesic effects of semax across different experimental paradigms, confirming cognitive performance improvements in preclinical models.[4] Panikratova et al. (2020) applied functional connectomic analysis to study semax’s effects on brain network organisation, providing neuroimaging-level evidence of altered functional connectivity consistent with enhanced cognitive processing.[5] The combined dopaminergic and serotonergic activation adds motivational and mood-regulatory dimensions to the cognitive profile — a multi-pathway nootropic mechanism that distinguishes semax from compounds acting on single neurotransmitter systems.

For context within the peptide landscape: most peptides studied for cognitive effects operate indirectly — through GH-mediated neuroprotection (sermorelin, CJC-1295) or through tissue-repair mechanisms with secondary neural benefits (BPC-157). Semax is unusual in targeting CNS neurotrophin pathways directly, making it one of the most mechanism-specific nootropic peptides in the current research landscape. The peptide epithalon provides an interesting parallel — while its mechanism (telomerase activation) is entirely different, it similarly targets a specific molecular pathway rather than operating through broad systemic effects.

Neuroprotection Context

The neuroprotection research on semax centres on its ability to activate the brain’s endogenous repair machinery after ischemic injury. Cerebral ischemia — the oxygen deprivation that occurs during stroke — triggers widespread neuronal death, and compounds that can upregulate neurotrophic gene expression during the critical post-ischemic window represent a significant research target. Dmitrieva et al. (2010) demonstrated that semax activates transcription of neurotrophins and their receptor genes after experimental cerebral ischemia, providing evidence for a direct neuroprotective mechanism.[3]

Filippenkov et al. (2024) advanced this research significantly, showing that ACTH-like peptides including semax can compensate for disrupted brain gene expression profiles following experimental stroke — essentially demonstrating that semax partially normalises the catastrophic transcriptomic changes caused by ischemia.[6] Glazova et al. (2021) extended semax’s neuroprotective profile to developmental neurotoxicity, showing that the compound attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure — suggesting neuroprotective relevance beyond acute ischemic injury.[7]

Most recently, Liu et al. (2025) identified a novel neuroprotective mechanism: semax targets the μ-opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury, opening a new mechanistic dimension beyond the established BDNF/neurotrophin pathway.[8] This expanding mechanistic profile — from BDNF upregulation to gene expression normalisation to opioid receptor modulation — suggests that semax neuroprotective effects may operate through multiple convergent pathways. For comparison, GHK-Cu has also shown neuroprotective potential through entirely different mechanisms (gene expression modulation and anti-inflammatory activity).

Semax Benefits

The semax benefits profile reflects its dual nootropic-neuroprotective mechanism, supported by both preclinical research and Russian clinical use:

• BDNF upregulation: Directly increases brain-derived neurotrophic factor and TrkB receptor expression in the hippocampus — the molecular foundation of synaptic plasticity and memory formation.[1]
• Neuroprotective in ischemia models: Activates neurotrophic gene transcription after cerebral ischemia, partially normalising gene expression disrupted by stroke.[3][6]
• Nootropic without hormonal effects: Retains the cognitive-active ACTH(4-10) fragment while eliminating adrenal cortex stimulation — cognitive enhancement without cortisol elevation.
• No cortisol stimulation: Despite being derived from ACTH, semax does not activate the HPA axis or stimulate cortisol release — a critical distinction from full-length ACTH.
• Dopamine and serotonin modulation: Activates both dopaminergic and serotonergic systems, supporting motivation, focus, and mood regulation.[2]
• Approved medication in Russia: Clinical approval since 2001 as a nootropic nasal spray provides a level of regulatory validation absent for most research peptides.
• Well-characterised mechanism: The ACTH-derived pharmacological rationale is well-understood, with multiple published mechanistic studies in English-language journals.[1][2][3]
• Expanding research profile: Recent studies continue to identify novel mechanisms including gene expression normalisation post-stroke and μ-opioid receptor modulation.[6][8]

Semax Side Effects

The semax side effects profile is generally favourable based on available data:

• Generally well-tolerated: Russian clinical experience since 2001 has not identified major safety concerns, supporting a favourable tolerability profile within the context of its approved use.
• No hormonal (adrenal) side effects: Unlike full-length ACTH, semax does not stimulate cortisol, aldosterone, or other adrenal hormones — the hormonal segments are absent from the ACTH(4-10) fragment.
• Nasal irritation: The most commonly noted effect with intranasal formulations — local irritation at the site of application, typically mild and transient.
• Limited Western safety data: Most safety characterisation derives from Russian clinical use rather than Western regulatory-grade safety studies. The absence of large-scale Western pharmacovigilance data is a limitation.
• Short duration of action: The short half-life means effects dissipate rapidly — a potential limitation for sustained cognitive support but also a safety advantage in terms of reversibility.

The semax side effects profile compares favourably to many GH-axis peptides that produce broader systemic effects. Unlike GHRP-6 or GHRP-2, which stimulate cortisol, appetite, and other hormonal pathways, semax’s CNS-targeted mechanism produces a narrower and generally milder side effect profile. The principal caveat is not the presence of known side effects but the absence of comprehensive Western safety data.

Half-Life

Semax has a short plasma half-life measured in minutes — characteristic of small peptide fragments that are rapidly cleared by circulating peptidases. However, the C-terminal Pro-Gly-Pro extension was specifically engineered to improve metabolic stability compared to the native ACTH(4-10) fragment, which would otherwise be degraded within seconds to minutes. This stabilisation strategy is pharmacologically analogous to how CJC-1295 uses Drug Affinity Complex (DAC) technology to extend the half-life of GHRH analogs, though the mechanisms differ.

The short circulating half-life does not necessarily limit functional duration: semax’s downstream effects — BDNF upregulation, neurotrophic gene transcription, neurotransmitter system modulation — operate on longer biological timescales than the peptide’s plasma presence. This is consistent with the principle that many peptide signalling molecules act as triggers rather than sustained effectors, initiating cascades that persist beyond the compound’s circulating presence. For comparison across peptide half-lives: ipamorelin has approximately a 2-hour half-life, sermorelin is 10-20 minutes, and epithalon operates on similarly short timescales with longer-duration downstream effects.

Limits of Current Evidence

• Not FDA or EMA approved: Semax has no regulatory approval outside Russia and former Soviet states. Unlike semaglutide and liraglutide (FDA-approved GLP-1 agonists) or tesamorelin (FDA-approved GHRH analog), semax lacks Western regulatory validation.
• Russian clinical approval provides some validation: Approval since 2001 as a nootropic nasal spray represents real regulatory review, but Russian approval standards differ from FDA/EMA requirements and may not satisfy Western evidence thresholds.
• More English-language data than many Russian-developed peptides: Semax has a growing body of English-language mechanistic publications, but still limited large-scale Western clinical trial data. Most human outcome data exists in Russian-language literature.
• Strong preclinical data, limited clinical translation: Animal model data for ischemia, BDNF upregulation, and behavioural effects is robust, but human outcome trials in Western literature are scarce. The gap between preclinical promise and clinical validation remains significant.
• Well-understood ACTH-derived mechanism provides confidence: The pharmacological rationale — isolating the cognitive-active ACTH(4-10) fragment — is grounded in well-established ACTH biology, which provides mechanistic confidence even where clinical data is limited.
• Long-term safety data is limited to Russian pharmacovigilance: Multi-year safety profiles from Western regulatory-grade monitoring do not exist.

Verdict

Semax is one of the most pharmacologically rational nootropic peptides in the research landscape. By isolating the cognitive-active ACTH 4-10 fragment — the region of adrenocorticotropic hormone responsible for neurotrophic and nootropic effects — and stabilising it with a Pro-Gly-Pro C-terminal extension, the semax peptide achieves targeted neurotrophic and neuroprotective activity without hormonal cross-talk. The semax BDNF upregulation data is compelling and mechanistically well-characterised, and its activation of dopaminergic and serotonergic systems provides a multi-pathway cognitive support profile.[1][2]

The Russian clinical approval since 2001 adds a layer of regulatory weight that most research peptides lack entirely — this is a compound that has been prescribed and monitored in clinical settings for over two decades, not merely studied in laboratory conditions. The expanding English-language research base — from BDNF upregulation to post-ischemic gene expression normalisation to spinal cord injury recovery — demonstrates a compound with a deepening rather than narrowing evidence profile.[3][6][8]

This semax review of the published evidence makes the limitation clear: outside Russia, semax remains investigational. The absence of FDA/EMA approval and large-scale Western clinical trials means that international regulatory frameworks do not recognise its efficacy claims. For researchers and clinicians evaluating nootropic peptides, semax presents a compound where the mechanistic rationale is strong, the Russian clinical experience is extensive, but the Western evidentiary standard has not yet been met. This positions it as one of the most interesting compounds to watch as the English-language evidence base continues to develop. The semax vs selank comparison is particularly instructive: both are Russian-developed nootropic peptides from the same institute, but semax targets BDNF/neurotrophin pathways while selank targets anxiolytic/immunomodulatory pathways — complementary rather than competing mechanisms.

FAQ

What is Semax?

Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for cognitive and neurotrophic effects. It was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, and has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray. It is not approved by the FDA or EMA.

Is Semax the same as ACTH?

No. Semax contains only the ACTH(4-10) fragment — seven amino acids from the cognitive-active region of the 39-amino-acid ACTH molecule. The segments responsible for adrenal cortex stimulation and cortisol production (positions 1-3 and 11-39) are absent. Semax retains nootropic and neurotrophic effects while eliminating hormonal activity.[1]

Does Semax increase cortisol?

No. Despite being derived from ACTH (which is the primary driver of cortisol production), semax does not stimulate the adrenal cortex or increase cortisol levels. The ACTH(4-10) fragment lacks the structural elements required for adrenal activation — this separation of cognitive from hormonal effects is the core pharmacological design principle of semax.

What is the difference between Semax and Selank?

Both are synthetic heptapeptides developed at the same Russian institute (Institute of Molecular Genetics, RAS) and approved in Russia as nasal sprays. However, they target different mechanisms: semax is an ACTH(4-10) analog that upregulates BDNF and activates dopaminergic/serotonergic systems for nootropic and neuroprotective effects. Selank is a tuftsin analog that modulates enkephalin metabolism for anxiolytic and immunomodulatory effects. They are complementary rather than interchangeable compounds.

Is Semax approved anywhere?

Yes. Semax has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray. It is not approved by the FDA, EMA, or other Western regulatory agencies. It is not classified as a controlled substance internationally.

Does Semax increase BDNF?

Yes. Dolotov et al. (2006) demonstrated that semax regulates BDNF and TrkB receptor expression in the rat hippocampus — providing direct evidence of neurotrophic factor upregulation. BDNF upregulation is considered the primary mechanistic basis of semax’s nootropic and neuroprotective effects.[1]

Is Semax FDA approved?

No. Semax is not FDA-approved for any indication. It remains a research compound in Western regulatory contexts. Its only regulatory approval is in Russia, where it has been an approved medication since 2001. For FDA-approved peptide-class therapeutics, see semaglutide, liraglutide, or tesamorelin.

References

1. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037
2. Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362768
3. Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-79. PMID: 19633950
4. Manchenko DM, et al. Nootropic and analgesic effects of Semax following different routes of administration. Ross Fiziol Zh. 2010;96(10):1014-1023. PMID: 21268834
5. Panikratova YR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. PMID: 32342318
6. Filippenkov IB, et al. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. 2024;13(1):18. PMID: 39767736
7. Glazova NY, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure. Neuropeptides. 2021;86:102117. PMID: 33418449
8. Liu R, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury. Br J Pharmacol. 2025;182(22). PMID: 40692165

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Semax is not approved by the FDA for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.

Selank (TP-7) is a synthetic heptapeptide developed by the Institute of Molecular Genetics at the Russian Academy of Sciences. It is structurally based on tuftsin — an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) naturally produced during immunoglobulin G cleavage — with a Pro-Gly-Pro stabilising extension that increases metabolic stability and confers distinct neuropeptide activity. Selank peptide was designed to combine anxiolytic and nootropic properties without the sedation, cognitive impairment, or dependence associated with benzodiazepine-class anxiolytics.[1][3]

Approved in Russia as an anxiolytic nasal spray since 2009, Selank occupies a unique position in the neuropeptide landscape: it is one of very few peptide-based compounds to achieve regulatory approval specifically for anxiety disorders. Its dual mechanism — combining the immunomodulatory heritage of its tuftsin backbone with GABAergic, serotonergic, and dopaminergic modulation — distinguishes it from conventional anxiolytics and from other research peptides such as BPC-157 or GHK-Cu that operate through entirely different pathways.[1][2][5]

Despite its Russian clinical approval, Selank remains largely unfamiliar in Western research circles. The majority of published clinical data exists in Russian-language journals, and it has not pursued FDA or EMA regulatory pathways. This creates an unusual evidence profile: genuine regulatory validation in one jurisdiction alongside limited peer-reviewed visibility in another.

Compound Profile

What Does Selank Actually Do?

At its core, Selank is an anxiolytic neuropeptide — sometimes referred to as the “anti-anxiety peptide” in the research community. In clinical studies conducted in Russia, it demonstrated anxiolytic effects comparable to phenazepam (a benzodiazepine) but without the sedation, cognitive impairment, or dependence that define benzodiazepine pharmacology.[3] This is its most distinctive pharmacological feature: Selank anxiety reduction operates through a fundamentally different mechanism than traditional anxiolytics.

The compound modulates multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and noradrenergic pathways are all influenced, creating a broad modulatory profile rather than the targeted receptor agonism seen with benzodiazepines or SSRIs.[1] This multi-system modulation may explain why Selank nootropic effects have been observed alongside its anxiolytic activity: reducing anxiety without sedation can itself improve cognitive performance, particularly under stress conditions.

Beyond its neurological effects, Selank retains the immunomodulatory activity of its parent peptide tuftsin. It influences IL-6 expression and inflammatory gene dynamics, connecting its neuropeptide activity to immune system modulation in a way that few other anxiolytic compounds achieve.[2][5] This dual anxiolytic-immunomodulatory profile makes Selank genuinely novel — it is not simply another anxiolytic, but a compound that bridges the neuroimmune interface.

How Selank Works

Selank’s mechanism begins with its structural heritage. The first four residues (Thr-Lys-Pro-Arg) comprise tuftsin — an endogenous tetrapeptide cleaved from the Fc domain of immunoglobulin G that serves as a natural immunomodulatory signal. Siebert et al. (2017) comprehensively reviewed tuftsin’s properties, documenting its role in macrophage activation, phagocytosis enhancement, and immune regulation.[2] By building on this immunopeptide scaffold, Selank inherits baseline immunomodulatory activity while the Pro-Gly-Pro extension confers both metabolic stability and distinct neuropeptide properties.

Vyunova et al. (2018) provided the most comprehensive review of Selank peptide‘s molecular mechanisms, establishing that the heptapeptide modulates GABAergic neurotransmission, influences serotonin and dopamine metabolism, and affects the expression of brain-derived neurotrophic factor (BDNF) and related signalling cascades.[1] The anxiolytic effect appears to involve allosteric modulation of GABA-A receptor sensitivity rather than direct agonism — a mechanistic distinction from benzodiazepines that may explain the absence of sedation and dependence.

Medvedev et al. (2014) provided direct clinical evidence, comparing Selank to phenazepam in patients with generalised anxiety disorder. The study found comparable anxiolytic efficacy with significantly better tolerability — no sedation, no cognitive impairment, and no withdrawal symptoms upon discontinuation.[3] This clinical head-to-head comparison remains one of the strongest pieces of evidence supporting Selank’s therapeutic profile, though the study was conducted in a Russian clinical setting with limited Western replication. These modulatory mechanisms contrast with the receptor-specific approaches seen in peptides like PT-141 or the GH-axis compounds such as ipamorelin and sermorelin.

Cognitive & Nootropic Support Context

The cognitive and nootropic support relevance of Selank operates through an indirect but well-characterised pathway: anxiety impairs cognition, and anxiolysis without sedation restores it. Unlike benzodiazepines — which reduce anxiety at the cost of cognitive performance — Selank’s non-sedating anxiolytic profile means cognitive function is preserved or enhanced under stress conditions.[1][3] This positions Selank nootropic effects as a secondary benefit of its primary anxiolytic mechanism rather than a direct cognitive enhancement.

Panikratova et al. (2020) studied the functional connectomics of Selank alongside Semax (another Russian-developed neuropeptide), examining how these neuropeptides influence brain network connectivity. The study documented changes in functional connectivity patterns consistent with improved cognitive processing efficiency under Selank.[4] While Semax targets a different neuropeptide pathway (melanocortin-derived), the comparative framework highlights Selank’s distinct cognitive and nootropic support profile — anxiolytic-driven rather than directly stimulatory. This mechanism differs fundamentally from peptides in the GH-axis family like CJC-1295 or tesamorelin, which support cognition indirectly through metabolic and neuroprotective pathways.

Neuroprotection Context

Selank’s neuroprotection profile emerges from two converging pathways: its immunomodulatory heritage and its anti-stress activity. Kolomin et al. (2014) demonstrated that Selank modulates the expression of inflammation-related genes, including IL-6 and other cytokine pathways, establishing a direct link between the peptide and neuroinflammatory regulation.[5] Given the increasingly recognised role of chronic neuroinflammation in neurodegenerative processes, this immunomodulatory activity positions Selank within the broader neuroprotection research landscape alongside compounds like GHK-Cu and BPC-157 that also influence inflammatory signalling.

Konstantinopolsky et al. (2022) extended the neuroprotective narrative by demonstrating that Selank attenuates aversive signs of morphine withdrawal in animal models.[6] This finding suggests modulatory effects on stress-related neural circuits and addiction pathways — areas where neuroprotective intervention may have significant implications. The anti-stress properties documented across multiple studies may confer neuroprotective benefit through reduced excitotoxicity and cortisol-mediated neuronal damage, though these mechanistic links remain to be fully elucidated. The peptide’s neuroprotective approach differs from that of Pal-GHK and TB-500, which operate through tissue repair and regenerative pathways.

Selank Benefits

The Selank benefits profile reflects its unique position as a tuftsin-derived anxiolytic neuropeptide with dual neuroimmune activity:

• Anxiolytic without sedation or dependence: Clinical comparison with phenazepam demonstrated comparable anxiety reduction without the cognitive impairment, sedation, or withdrawal symptoms associated with benzodiazepines.[3]
• Nootropic under stress: By reducing anxiety without impairing cognition, Selank may enhance cognitive performance in stress conditions — a secondary benefit of its primary anxiolytic mechanism.[1][4]
• Immunomodulatory activity: Retains tuftsin’s immunomodulatory properties, modulating cytokine expression (IL-6) and inflammatory gene dynamics — a feature absent from conventional anxiolytics.[2][5]
• No withdrawal symptoms reported: Across clinical studies, no dependence or withdrawal effects have been documented — a significant distinction from benzodiazepines and many other anxiolytic compounds.[3]
• Regulatory approval in Russia: One of the very few peptide-based compounds to achieve clinical approval specifically for anxiety disorders, providing a level of regulatory validation uncommon in the peptide research space.
• Unique dual anxiolytic-immune mechanism: The combination of tuftsin-derived immunomodulation with GABAergic/monoaminergic anxiolysis is genuinely novel — no other approved anxiolytic operates through this neuroimmune bridge.[1][2]

Selank Side Effects

The Selank side effects profile is notably benign compared to conventional anxiolytics, though this must be contextualised against the limitations of the available evidence base:

• No sedation: Unlike benzodiazepines, Selank does not produce drowsiness or psychomotor impairment in clinical studies — this is one of its defining pharmacological features.[3]
• No dependence or withdrawal: No cases of dependence, tolerance, or withdrawal symptoms have been reported across published clinical data.[3]
• Mild fatigue: Rarely reported in some studies, generally transient and self-resolving.
• Limited Western safety data: Most tolerability information comes from Russian clinical trials. Independent Western replication of safety profiles is sparse, meaning the full side effect spectrum may not be captured in the English-language literature.

The Selank side effects profile is one of the compound’s strongest selling points, but it should be interpreted cautiously. The absence of reported adverse effects may reflect genuine tolerability, small study populations, publication bias in Russian-language journals, or some combination of these factors. Compared to the well-characterised side effect profiles of compounds like semaglutide or liraglutide — where large Western RCTs have mapped adverse events in detail — the Selank safety dataset remains thin by international standards.

Half-Life

Selank has a short plasma half-life, estimated at several minutes — characteristic of small peptides vulnerable to enzymatic degradation. However, the Pro-Gly-Pro C-terminal extension provides meaningful improvement over native tuftsin’s extremely rapid clearance. This glyproline tail is a deliberate pharmacokinetic design feature: the Pro-Gly-Pro motif is known to confer resistance to peptidases while also possessing independent neuropeptide activity.[1]

The short half-life positions Selank alongside other rapidly-cleared peptides like gonadorelin and sermorelin, where the downstream biological effects — changes in gene expression, neurotransmitter modulation, immune signalling — persist substantially longer than the peptide’s circulating presence. Clinical use in Russia has employed intranasal delivery, which provides rapid absorption and partially circumvents first-pass hepatic metabolism.

Limits of Current Evidence

• Russian-language literature dominance: The majority of clinical data for Selank is published in Russian-language journals, limiting accessibility and peer review by the broader international research community.
• Limited Western replication: While the compound holds Russian regulatory approval, no large-scale Western RCTs have independently replicated its clinical efficacy or safety profile.
• Not FDA/EMA approved: Selank has not pursued regulatory approval outside Russia/CIS. Unlike semaglutide, tirzepatide, or tesamorelin — which have undergone rigorous Western regulatory review — Selank’s approval pathway followed Russian regulatory standards.
• Small study populations: Most published studies involve relatively small sample sizes, limiting statistical power and generalisability.
• Mechanism not fully elucidated: While the GABAergic and monoaminergic effects are documented, the precise molecular targets and signalling cascades remain to be fully characterised. The Selank tuftsin immunomodulatory angle is better understood than its anxiolytic specifics.
• Publication bias considerations: The predominantly Russian evidence base may be subject to publication bias patterns different from those in Western peer-reviewed literature.

Verdict

Selank represents an innovative approach to anxiolytic design — building on the endogenous immunopeptide tuftsin to create a compound with dual anxiolytic and immunomodulatory properties. Its structural elegance is genuine: using a naturally occurring immune signalling peptide as a scaffold for neuropeptide drug design is conceptually compelling, and the clinical data from Russia supports its anxiolytic efficacy.[1][2][3]

The Selank vs Semax comparison illustrates its niche: while Semax targets the melanocortin pathway for cognitive enhancement, Selank targets the neuroimmune interface for anxiolysis.[4] The absence of sedation and dependence — consistently reported across clinical studies — is its most distinctive and valuable feature, differentiating it from the benzodiazepine class in a clinically meaningful way.[3]

However, the limited Western peer-reviewed data means the evidence base doesn’t meet the standards researchers typically expect for confident conclusions. This Selank review of the available literature confirms that the Russian clinical approval provides regulatory validation, but it is not equivalent to the FDA or EMA review processes that compounds like retatrutide or tirzepatide have undergone. For now, Selank should be evaluated as a promising but incompletely validated anxiolytic neuropeptide — one where the concept is compelling, the preliminary data is encouraging, and the independent replication is still pending.

FAQ

What is Selank?

Selank is a synthetic heptapeptide based on tuftsin — an endogenous immunomodulatory tetrapeptide — with a Pro-Gly-Pro stabilising extension. Developed by the Institute of Molecular Genetics at the Russian Academy of Sciences, it is classified as an anxiolytic neuropeptide with dual anxiolytic and immunomodulatory properties. It is approved in Russia as a nasal spray for anxiety disorders.[1]

Is Selank approved anywhere?

Yes. Selank has been approved in Russia and CIS countries as an anxiolytic nasal spray since 2009. It is not approved by the FDA, EMA, or any other Western regulatory agency. Its Russian approval provides a level of clinical validation, though the regulatory standards differ from Western approval pathways.[3]

What is the difference between Selank and Semax?

Both are synthetic neuropeptides developed at Russian research institutes, but they target different pathways. Selank is a tuftsin analog that primarily provides anxiolytic and immunomodulatory effects through GABAergic and monoaminergic modulation. Semax is an ACTH(4-7) analog that primarily targets the melanocortin pathway for cognitive enhancement and neuroprotection. They are sometimes studied together as complementary neuropeptides.[4]

Does Selank cause sedation?

No. One of Selank’s defining features is that it produces anxiolytic effects without sedation or psychomotor impairment. In clinical comparisons with the benzodiazepine phenazepam, Selank showed comparable anxiety reduction without the sedative side effects.[3]

Is Selank addictive?

No dependence, tolerance, or withdrawal symptoms have been reported in published clinical studies of Selank. This distinguishes it from benzodiazepines and many other conventional anxiolytics, which carry well-documented dependence risks.[3]

What is tuftsin and how does it relate to Selank?

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide produced during the enzymatic cleavage of immunoglobulin G. It plays roles in macrophage activation, phagocytosis, and immune regulation. Selank is a synthetic analog that extends the tuftsin sequence with Pro-Gly-Pro, providing metabolic stability and neuropeptide activity while retaining the immunomodulatory properties of the parent peptide.[2]

Is Selank FDA approved?

No. Selank has not received FDA approval for any indication and has not entered the FDA regulatory pathway. It is approved only in Russia and CIS countries. Outside these jurisdictions, it is classified as a research compound. It is not a controlled substance internationally.

References

1. Vyunova TV, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. PMID: 30255741
2. Siebert A, et al. Tuftsin — Properties and Analogs. Curr Med Chem. 2017;24(34):3711-3727. PMID: 28745220
3. Medvedev VE, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr. 2014;114(7):17-22. PMID: 25176261
4. Panikratova YR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. PMID: 32342318
5. Kolomin T, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-58. PMID: 24291245
6. Konstantinopolsky MA, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):785-789. PMID: 36322304

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Selank is not approved by the FDA for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.